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ABSTRACT 
Ben Cooper 
Degree: MSc by Research 
Thesis title: Extracorporeal shock wave for the treatment of chronic 
venous ulcers: A pilot study 
 
This thesis reports a pilot study investigating the use of extracorporeal shock wave 
therapy (ECSW) in the treatment of chronic venous ulcers. The studies primary 
aim was to assess the clinical effectiveness of this treatment when combined with 
current best practice, multilayer compression bandaging. 
Venous ulceration of the lower limbs is a well-recognised, chronic condition. It 
affects a significant proportion of the population, results in reduced quality of life 
and is associated with substantial financial burden to health care systems. 
ECSW was first put to clinical use in the treatment of kidney stones (urolithiasis) 
and later in the treatment of orthopaedic non-union fractures. More recently, the 
ability of ECSW to improve the healing of soft tissue wounds has been assessed. 
A review of the current literature base revealed a limited number of clinical studies 
which included venous ulceration in their cohort. Despite this, positive outcomes 
were reported including complete wound healing in around a third of patients, 
improved healing rates and reductions in pain and exudate levels. Justification for 
a study focusing upon the effect of ECSW in the treatment of this specific condition 
was established, including the need for focus upon quality of life outcomes. 
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Quantitative methodology was employed in the structuring of a prospective pilot 
study, utilising a before-after design. 28 participants were recruited, none were 
lost to follow up. ECSW was administered alongside current best practice 
treatment, simple primary wound dressings and multilayer compression therapy. 
Treatment was delivered at two week intervals for a maximum of six treatments, 
with study follow up at 6 months. Wound healing, effect upon pain, exudate level 
and impact upon quality of life were measured to establish clinical effectiveness. 
Through discussion of study results, this thesis concludes that ECSW appears to 
be a safe treatment modality, beneficial in the management of longstanding, large 
ulcers, not responding to multilayer compression therapy. 
Building upon the findings of this study, further research is required to validate 
the use of ECSW in the treatment of chronic venous ulceration. 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: Extracorporeal; shock wave; ECSW; venous ulcer; leg ulcer; 
acoustic wave; chronic ulcer. 
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CHAPTER 1 - INTRODUCTION AND BACKGROUND 
1.1 Introduction 
Venous ulceration of the lower limbs is a well-recognised, chronic condition 
affecting a significant proportion of the population and is associated with 
substantial financial burden to health care systems (d Baumgartenc 2002, Ellison, 
Hayes et al. 2002). 
Extracorporeal shock wave therapy (ECSW) is proposed as a new modality of 
treatment in the management of chronic venous ulcers. The primary aim of this 
study is to assess its clinical effectiveness when combined with current best 
practice, multilayer compression bandaging. 
 
1.2 Structure of the thesis 
The first chapter of this thesis aims to provide an informative background to the 
research topic, introducing the underlying condition and the treatment being 
investigated. With this established, chapter two examines the existing knowledge 
base by way of literature review, seeking a specific context in which to frame the 
need for this study. 
Chapter three’s purpose is twofold, introducing study aims and outcome measures 
in relation to the theory of research methodology, before outlining the study 
design and methods. 
Results are presented and summarised in chapter four before discussion with 
consideration of the existing and current knowledge base in chapter five. Within 
this same chapter, limitations, further research needs and implications for practice 
are discussed before drawing conclusion in chapter six. 
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1.3 Background - Lower limb venous ulceration 
1.3.1 Defining venous ulceration 
The terminology used to define venous ulceration varies between studies and 
between clinical guidelines. NICE guidelines now discuss venous ulceration in 
terms of uncomplicated venous ulcers and non-healing venous ulcers, the later 
meeting the criteria of not having healed after 2 to 3 months of standard treatment 
(National Institute for Health and Care Excellence 2012). SIGN guidelines provide 
an explicit definition whereby chronic venous leg ulcers are defined as an open 
lesion between the knee and the ankle joint which has remained unhealed for at 
least 4 weeks and occurs in the presence of venous disease (SIGN 2010). 
Within this thesis the term venous ulcer or ulceration has been used when 
discussing the overall condition and aims to include both uncomplicated and non-
healing venous ulcers. Chronic venous ulcer or ulceration has been used to define 
non-healing venous ulcers, not responding to standard treatment and in situ for 
greater than 4 weeks. 
 
1.3.2 Aetiology, epidemiology and natural history 
The causes of leg ulceration are varied and often multifactorial (Smith 2006); 
primary aetiological factors include venous insufficiency, arterial insufficiency and 
diabetes (Mekkes, Loots et al. 2003). Studies have shown that 70 to 80% of 
patients with leg ulcers have a venous component and that they are the most 
common type of leg ulceration treated in the community (Valencia, Falabella et al. 
2001, Crane, Cheshire 2008). 
 3 
 
Leg ulcers of venous aetiology are the manifestation of severe, chronic venous 
disease (van Gent, Wilschut et al. 2010); prevalence is estimated at between 
0.3% and 0.5% (per 1000 population) in the United Kingdom, which increases in 
the over 65 age group (d Baumgartenc 2002, Vowden, Vowden 2009). The natural 
history of the disease is one of a continuous cycle of healing and breakdown over 
decades (Smith 2006, Raju 2010). The healing of active venous ulcers can be slow 
and recurrence rates high (Egemen, Ozkaya et al. 2012). 
Patients with venous ulcers have a significantly impaired quality of life including 
experience of reduced mobility, pain, stress and loss of dignity (Persoon, Heinen 
et al. 2004, Wilson 2004). Social isolation can be common place and is frequently 
associated with malodorous wounds, swelling and anxiety around exudate levels 
(Walters, Morrell et al. 1999, Herber, Schnepp et al. 2007). 
Treatment of this condition results in a considerable cost to the NHS and accounts 
for 1 to 3% of the entire healthcare budget, a cost estimated in 2002 as between 
£300m and £400m (Ellison, Hayes et al. 2002, Ragnarson Tennvall, Hjelmgren 
2005, Carradice, Mazari et al. 2011). 
 
1.3.3 Pathophysiology 
Ulceration occurs in the presence of venous disease as a result of chronic venous 
insufficiency and ambulatory venous hypertension (Eberhardt, Raffetto 2005, 
Smith 2006). Most commonly, chronic venous insufficiency is attributable to a 
defect or weakness of the vein wall, leading to valve incompetence of the deep, 
superficial or perforating veins of the leg (Nicolaides, Cardiovascular Disease 
Educational and Research Trust et al. 2000, Schmid-Schonbein, Takase et al. 
2001). The presence of an ineffectual calf muscle pump mechanism, the method 
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by which venous pressure is raised and blood propelled through the vein toward 
the heart, is a known factor contributing to venous hypertension (Beebe-Dimmer, 
Pfeifer et al. 2005, O'Brien, Edwards et al. 2012). In turn, the efficiency of the calf 
muscle pump relies upon competency of the venous valves and good mobility, 
especially of the ankle joint (Dixy, Brooke et al. 2003, Meissner, Moneta et al. 
2007). 
Valve incompetence and venous hypertension leads to microcirculatory skin 
changes and localised tissue damage (Mekkes, Loots et al. 2003, Etufugh, Phillips 
2007). Risk factors for the development of chronic venous insufficiency have been 
widely thought to include age, gender, genotype, obesity, and pregnancy 
(Valencia, Falabella et al. 2001, Bergan, Kumins et al. 2002). Complications as a 
result of deep vein thrombosis have been shown to cause chronic venous 
insufficiency attributable to either valve damage or vein obstruction (Kahn, 
Ginsberg 2002, Thomas 2013). 
It is considered likely that behavioural factors such as prolonged standing or 
generally reduced mobility also have an influence upon the development of chronic 
venous insufficiency (Kahn, Ginsberg 2002, Eberhardt, Raffetto 2005).  
An increasingly frequent and under-reported cause of venous insufficiency arises 
in cases of intravenous drug misuse (Del Giudice 2004). The cause of venous 
insufficiency amongst intravenous drug users stems from deep vein thrombosis 
and repeated vein trauma at injection sites, affecting the superficial and deep 
veins of the lower limb (Pieper, Templin 2001, Senbanjo, Strang 2011).  
Two main mechanisms have been proposed to account for the tissue damage and 
subsequent ulceration that can occur as a result of chronic venous insufficiency. 
The fibrin cuff hypothesis, postulates that venous hypertension leads to increased 
exudation of fibrin, a protein involved in the clotting of blood, into the surrounding 
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tissues and leads to the formation of fibrin cuffs around capillaries which impairs 
gas exchange, leading to tissue ischemia (Hahn, Unthank et al. 1999, Smith 
2006). 
The leukocyte trapping hypothesis, postulates that white blood cells (leukocytes) 
which have become trapped in the microcirculation, migrate into surrounding 
tissues and lead to an inflammatory response with impairment of normal 
proliferation and skin healing (Abbade, Lastória 2005, Sevim, Unal et al. 2014). 
 
1.3.4 Quality of life 
Chronic venous ulceration is a condition whereby people suffer with an open 
wound and associated morbidity for many months, in some cases years and 
decades (Reichenberg, Davis 2005). Living with chronic venous ulceration leads 
to substantial impairment of quality of life (QOL). Severity of the condition, 
specifically size and duration of ulceration have been shown to be indicative of the 
impact upon a person’s QOL (Franks, Moffatt 2006). Studies have consistently 
revealed poorer perceived health in the domains of pain, mobility, physical and 
social functionality in groups of men and women living with a chronic venous ulcer 
(González‐Consuegra, Verdú 2011). 
Studies utilising validated QOL assessment tools, such as the SF-36 questionnaire, 
have highlighted age as a key factor affecting QOL amongst those suffering from 
chronic venous ulceration, with the most elderly experiencing poorer QOL (Kaplan, 
Criqui et al. 2003, Hopman, VanDenKerkhof et al. 2014). Measurement of QOL 
provides understanding of the impact disease has upon the patient, yet many 
studies investigating venous disease and the treatment of chronic venous 
ulceration fail to consider QOL outcomes (Andreozzi, Cordova et al. 2005). Both 
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generic and disease specific QOL questionnaires have been shown to be useful in 
assessment; studies suggest their combined use provides a more comprehensive 
and useful clinical appraisal (de Vries, Ouwendijk et al. 2005, Engelhardt, Spech 
et al. 2014). 
The physical problems associated with chronic venous ulceration result in 
psychological complications such as anxiety, depression and altered body image, 
further contributing to greatly reduced QOL (Walters, Morrell et al. 1999, Maddox 
2012). These issues are compounded by socially restrictive dressing regimes and 
large, bulky compression bandages (Smith, Guest et al. 2000). 
 
1.3.5 Pain 
Venous ulcers have not always been considered as painful when discussed in 
literature; some, mainly older studies completely disassociated pain with venous 
ulceration, whilst others consider venous ulceration to be far less painful than 
arterial ulceration. The majority of more recent studies recognise and accept that 
there is an association between venous ulceration and pain (Valencia, Falabella et 
al. 2001, Abbade, Lastória 2005, Edwards, Finlayson et al. 2014). 
Pain is now regularly cited as the primary concern of patients living with a venous 
ulcer and directly affects several key QOL domains (Herber, Schnepp et al. 2007). 
Both neuropathic and nociceptive pain types have been linked to venous leg ulcers 
(Jørgensen, Friis et al. 2006, Woo, Sibbald et al. 2008). The former relates to 
damaged nerve tissue and the later results from actual tissue damage (Tsuda, 
Inoue et al. 2005). Clinical assessment to define type of pain appears to remain 
subjective and mainly involves the patient’s description of sensation. Descriptions 
of neuropathic pain often include terms such as burning or shooting pain 
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sensations, whereas nociceptive pain has often been portrayed as sharp, aching 
or throbbing pain sensations (Woolf, Mannion 1999, Price, Fogh et al. 2007). 
Chronic venous ulcers are susceptible to recurrent infection; the association 
between infection and wound pain is well documented. When present, infection 
almost certainly contributes to the pain burden of chronic venous ulcers (Cutting, 
White et al. 2013).  
The prevalence of pain amongst those suffering venous ulceration is difficult to 
determine. A Cochrane Collaboration review focusing upon topical agents or 
dressings for pain in venous ulcers cites the prevalence of pain for this condition 
as ranging from 17% to 65%; this is certainly collaborated by other venous ulcer 
studies where pain prevalence is generally concluded to be in excess of 60% 
(Briggs, Nelson 2001, Nemeth, Harrison et al. 2003, Heinen, Persoon et al. 2007, 
Edwards, Finlayson et al. 2014). 
Yet pain is much neglected as an outcome measure in studies where total healing 
or rate of healing tends to take precedence (Cooper, Hofman et al. 2003). This 
may in part be due to the difficulty of measuring pain, a subjective experience 
shaped by many factors (Younger, McCue et al. 2009). Simple, validated, rating 
scales have been successfully employed in a number of studies, including the use 
of visual analogue scales to record patient reported pain levels (Ferreira-Valente, 
Pais-Ribeiro et al. 2011). The limitation of these assessment tools lies in their 
inability to describe type or quality of pain, focusing only upon pain intensity 
(Cooper, Hofman et al. 2003). 
Studies exploring the use of visual analogue scores (VAS) to evaluate pain have 
suggested that a clinically significant change or reduction in score may be 
dependent upon baseline severity, with those registering a greater baseline score 
requiring a greater reduction to achieve clinical significance. Despite this, several 
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studies have concluded that an approximately 30% shift in VAS may constitute a 
clinically significant change (Bird, Dickson 2001, Farrar, Young et al. 2001, Jensen, 
Chen et al. 2003). 
 
1.3.6 Exudate 
Large volumes of wound exudate are synonymous with chronic venous ulceration, 
causing further discomfort and pain through excoriation of the skin and 
psychological distress associated with leakage and odour (Edwards, Finlayson et 
al. 2014). 
In theory wound exudate should be quantifiable utilising a continuous 
measurement scale. Few techniques have been investigated; the method of 
weighing dry and wet dressings to assess exudate quantity has been described as 
ineffectual and impractical (Cutting 2003, Dealey, Cameron et al. 2006). In daily 
practice volume of exudate is recorded as low, medium or high and remains a 
subjective measurement which will vary between practitioners (Grey, Harding et 
al. 2006). 
The role of wound exudate in the healing of venous ulcers is poorly understood; 
several studies have inferred that venous ulcer exudate can significantly inhibit 
the process of angiogenesis leading to increased healing times (Drinkwater, Smith 
et al. 2002, Ulrich, Lichtenegger et al. 2005). 
 
1.3.7 Current treatment and best practice 
The assessment and diagnosis of venous disease as the underlying ulcer aetiology 
involves an array of healthcare professionals (Brem, Kirsner et al. 2004). National 
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guidelines indicate assessment of ankle brachial indices (ABI) should be performed 
to rule out arterial disease, alongside further diagnostic assessments including 
duplex ultrasound imaging to identify venous reflux (SIGN 2010, Lurie, Comerota 
et al. 2012). Treatment is usually carried out and overseen by community and 
hospital nursing teams, in many cases via specialist ulcer clinics (Maddox 2012, 
Edwards, Finlayson et al. 2013). The truly chronic nature of the condition can in 
some cases lead to the need for lifelong treatment (Collins, Seraj 2010, Van 
Hecke, Verhaeghe et al. 2011). 
The current gold standard in the management of venous ulcers revolves around 
high compression multilayer bandaging (SIGN 2010). Multilayer compression 
bandaging aims to improve venous return and reduce venous hypertension 
(Stansal, Lazareth et al. 2013, Nelson, Harrison 2014). A Cochrane review of 
randomised controlled trials identified seven studies comparing compression with 
no compression and concluded that compression increases ulcer healing rates 
when compared to no compression (Cullum, Nelson et al. 2001). 
In the United Kingdom, elastic multi-component bandages such as four layer 
bandaging and comparative two layer systems are used; these consist of an initial 
layer of orthopaedic wool, an elastic bandage and an elastic cohesive bandage as 
the outer layer (Todd 2011, Partsch 2013). The high pressure is sustained for a 
considerable time allowing for a weekly change of dressings. With multilayer 
compression therapy, healing rates of around 70% at six months have been 
achieved in specialist clinics. Twelve month recurrence rates vary greatly between 
26% and 69% (Iglesias, Nelson et al. 2004, Barwell, Taylor et al. 2000). 
Both four layer and two layer compression bandaging systems are utilised in 
practice; opinion has traditionally been divided regarding which provides the best 
wound healing outcome (Moffatt, Mccullagh et al. 2003, Mosti, Mattaliano et al. 
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2008). A Cochrane systematic review concluded that each system yields similar 
healing rates and that both are appropriate treatment options (O'Meara, Cullum 
et al. 2012). 
Several systematic reviews and current best practice guidelines recommend 
simple, non-adherent wound dressings be used alongside compression treatment  
(O’Donnell Jr, Lau 2006, SIGN 2010). Consistently, no one dressing type has 
prevailed in clinical trials as superior in terms of number of ulcers healed. Given 
this outcome consideration should be given to the absorption of exudates and the 
protection of surrounding tissues in selection of a primary wound dressing (Tang, 
Marston et al. 2012, Thomas 2013, Lazarus, Valle et al. 2014). 
 
1.3.8 Variables affecting response to compression therapy 
Poor compliance with medical treatment by those suffering chronic, long term 
conditions is well reported (Roebuck, Liberman et al. 2011). Several studies have 
examined the issues surrounding poor compliance with compression bandaging; 
unequivocally the primary cause is lack of patient education and poor provision of 
treatment information (Edwards 2003, Annells, O'Neill et al. 2008). Beyond this 
explanation several modalities of the treatment impede patient compliance. The 
application of compression bandaging adds significant bulk to the leg which can 
cause problems with the fit of clothing and footwear (Stansal, Lazareth et al. 
2013). Poor application technique can lead to patients experiencing pain, oedema 
and tissue damage; the later due to excessive pressure upon prominent areas, in 
much the same way as the development of pressure sores (Todd 2011). 
Compression has proven effective in the treatment of venous ulcers, with the 
highest success found in ulcers of less than six months duration and of less than 
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5cm2 wound area (Watson, Kang'ombe et al. 2011, Nelson 2001a). Stubborn, hard 
to heal venous ulcers, older in duration and unresponsive to compression therapy 
have led to the investigation and development of many novel treatments, often 
referred to as advanced wound care techniques (Rippon, Davies et al. 2007). 
 
1.4 Background - Extracorporeal shock wave therapy 
1.4.1 Shock waves 
Shock waves are most easily described as pulses of acoustic, or sound energy with 
very specific characteristics (Mittermayr, Hartinger et al. 2012.). Acoustic waves 
manifest and spread as disruptions in surrounding pressure levels, the most 
common example are acoustic audio waves which create a small disturbance 
through a medium such as air and can be audible to the human ear (Rassweiler, 
Knoll et al. 2011). Acoustic pressure levels are expressed in terms of frequencies; 
the entire range of frequencies can be divided into three sections: audio, ultrasonic 
and infrasonic. Clinically useful acoustic shock waves fall into the ultrasonic 
frequency bracket (Ogden, Tóth-Kischkat et al. 2001). 
The waveform of each acoustic shock wave pulse consists of a quickly achieved 
(<1 nanosecond), sharp spike of high amplitude acoustic pressure which is 
immediately followed by a slightly more drawn out period (several microseconds) 
of lower amplitude pressure (Ito, Fukumoto et al. 2009, Goertz, Lauer et al. 2012). 
There are two effects observed in the creation of a shock wave pulse; the primary 
impact of energy in the initial spike of high amplitude pressure and the secondary 
impact of energy released via cavitation bubbles (Ogden, Tóth-Kischkat et al. 
2001). Cavitation bubbles are created by the initial shock wave propagation and 
release large amounts of energy upon their collapse. It has been suggested that 
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the effect of cavitation may be responsible for some clinical therapeutic effects, 
possibly more so than the initial high amplitude pressure release itself (Nishida, 
Shimokawa et al. 2004, Gerdesmeyer, von Eiff et al. 2005). 
The characterisation of shock waves often includes a description of energy flux 
density, the rate at which energy is transferred through the physical medium. A 
low or high flux density will directly result in the delivery of low or high levels of 
energy. Lower flux densities appear to be associated with therapeutic effects; 
adversely, a high flux density results in destructive outcomes as seen in the 
treatment of urinary calcinosis (Rassweiler, Knoll et al. 2011, Antonic, Mittermayr 
et al. 2011). 
Shock waves are generated through the process of converting electric energy into 
acoustic energy. This is achieved via a transducer utilising one of the following 
three methods currently being used in clinical practice: electromagnetic 
generation utilises a strong magnetic field to create a slow, low pressure acoustical 
pulse; piezoelectric generation relies upon the rapid contraction and expansion of 
piezoelectric crystals, achieved through the application of a high voltage pulse and 
electrohydraulic, whereby a shock wave pulse is released by high voltage electrode 
water vaporisation (Ogden, Tóth-Kischkat et al. 2001, Mouzopoulos, Stamatakos 
et al. 2007). 
 
1.4.2 Clinical use 
Extracorporeal shock waves were first put to clinical use during the 1970s in the 
treatment of urolithiasis, whereby kidney stones (urinary calcinosis) are broken 
up by the shock wave energy (Shrivastava 2005). Since then their application has 
been extended to the therapeutic treatment of fractured bones with an interrupted 
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healing process (non-union fractures), tendon injury and osteonecrosis, a 
condition whereby bone breaks down faster than it can be replenished (Schaden, 
Thiele et al. 2007). 
More recently, its ability to improve the healing of wounds, ulcers and burns has 
been assessed. The incidental discovery that shock waves may have an effect 
upon wound healing was made around 2007 (Schaden, Thiele et al. 2007, Arnó, 
García et al. 2010, Mittermayr, Hartinger et al. 2012.); the treatment in this 
context has remained novel.  
The mechanism of how ECSW may aid wound healing is poorly understood at 
present, however several animal model studies have shown increased levels of 
signal proteins (vascular endothelial growth factor (VEGF) and factor HIF-1alpha) 
following treatment. These proteins are in part responsible for the restoration of 
tissue oxygen supply when blood circulation is inadequate (Wang, Wang et al. 
2004, Chen, Wang et al. 2004, Nishida, Shimokawa et al. 2004). In humans, 
ECSW has been shown to promote the formation and development of blood vessels 
(angiogenesis) and to reduce inflammation (Wang, Yang et al. 2011). This 
angiogenic process appears to be stimulated by the application of shock waves 
and plays an important role in wound healing (Stojadinovic, Elster et al. 2008, 
Mittermayr, Hartinger et al. 2012.). In addition ECSW may, through the 
application of shear stress forces via the cavitation effect, alter the physical 
properties of endothelial cells (Mariotto, Cavalieri et al. 2005). 
The use of ECSW to treat soft tissue wounds is an innovative therapy which has 
slowly emerged over the last ten years. Its effectiveness in the management of 
specific wound subgroups is unknown. Review of the existing evidence and 
knowledge base is required to justify the study of its use in the treatment and 
management of chronic venous ulceration. 
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CHAPTER 2 - LITERATURE REVIEW 
Extracorporeal shock wave therapy in the management and treatment of 
lower limb venous ulceration 
 
2.1 Hierarchy of evidence 
At the foundation of evidence based practice there exists an accepted hierarchy 
of evidence. This hierarchy gives most credence to research outcomes which have 
the highest levels of validity, achieved via specific methodology (Evans 2003, 
Merlin, Weston et al. 2009). It is broadly accepted that randomised controlled 
trials (RCTs) are superior to non-randomised, experimental designs and 
observational studies, with case studies and reports regarded as far poorer 
sources of evidence (Hadorn, Baker et al. 1996, Sprague, McKay et al. 2008). 
Systematic reviews incorporating meta-analysis of data from multiple studies 
often sit at the very peak of the evidence hierarchy (Jones 2010). Systematic 
reviews published by the highly regarded Cochrane Collaboration aim to provide 
unbiased overviews of evidence through the use of rigorous methodologies and 
explicit literature search strategies (Haines, McKnight et al. 2008). 
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Figure 1 – Evidence hierarchy 
 
(Donatell 2015) 
 
Though the type of evidence hierarchy illustrated in figure 2 is well established 
and broadly accepted, its legitimacy has frequently been challenged. It has been 
suggested that evidence based practice requires the acknowledgement of 
experiential and reflective research methodologies and that the stature of this type 
of evidence should be elevated (Petticrew, Roberts 2003). These approaches 
within the conventional hierarchy of evidence are considered weak, yet many 
believe they better represent the reality of daily practice where the rigorously 
controlled conditions of an RCT are unlikely to be replicated or applicable to unique 
patient characteristics (Mantzoukas 2008, Concato 2004). 
In the review of literature pertaining to the use of ECSW in the treatment of lower 
limb venous ulceration, the intent is to seek out and consider all available evidence 
ranging from systematic review of RCTs to individual case study. The aim will be 
to deliver a comprehensive overview of the research outcomes informing the basis 
of this study. 
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2.2 Search strategy 
The well-defined and validated PICO acronym and concept was used to develop 
the search strategy for this review. The framework, which focuses upon four 
essential study components: Population, Intervention, Comparison and Outcome 
(Birch, Eady et al. 2003), was used to construct search terminology and to define 
relevant questions (Gerrish, Lacey 2010, Schardt, Adams et al. 2007). 
Cochrane Collaboration methodology suggests that extensive, systematic search 
strategies should not only include the use of text words, potentially found in titles 
and abstracts, but also indexed keywords often unique to individual databases; 
one such example would be the use of MeSH descriptors (Jadad, Cook et al. 1998, 
Higgins, Green 2008). 
Table 1 shows the refined search string utilised in the literature search. Table 2 
summarises all search results; The Scottish Intercollegiate Guidelines 
Network (SIGN) adapted algorithm (Appendix A) was used to classify study 
designs (Scottish Intercollegiate Guidelines Network (SIGN) 2014). 
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Table 1 – Search term string 
 
 
 
 
 
 
 
 
 
 
Table 2 – Search of electronic databases - results 
Database Results (n) 
MEDLINE 
EMBASE 
CINAHL 
CENTRAL (Cochrane) 
Web of science 
Total 
263 
204 
28 
10 
132 
637 
Duplicate studies removed 
Irrelevant studies removed 
Total for appraisal 
307 
323 
7 
 
 
Of the 637 results initially returned, 307 were identified as duplicates and 
removed. The titles and abstracts of the remaining 330 articles were reviewed and 
evaluated for relevance. A large number, 323 in all, were found to be irrelevant 
and comprised mainly of studies concerned with the use of ECSW for orthopaedic 
#1 MeSH descriptor: [Ultrasonic Surgical Procedures] explode all trees 
#2 MeSH descriptor: [Ultrasonic Therapy] explode all trees 
#3 MeSH descriptor: [Sound] this term only 
#4 MeSH descriptor: [High-Energy Shock Waves] explode all trees 
#5 (Shockwave* or (shock* near wave*)) 
#6 Ultraso*  
#7 Lithotrip*  
#8 ESWT  
#9 ECSW  
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9  
#11 MeSH descriptor: [Leg Ulcer] explode all trees 
#12 ((varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or 
(stasis next ulcer*) or (crural next ulcer*) or "ulcer cruris" or "ulcer* cruris")  
#13 #11 or #12  
#14 #10 and #13 
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application including the treatment of non-union fractures, tendinopathies and 
osteonecrosis. The treatment of burns, surgical skin flaps and diabetic foot ulcers 
also featured within the group of studies excluded. A single study was available in 
German language format only and therefore also excluded; in retrospect further 
endeavour to obtain translation of this paper should have been sought and may 
have resulted in its inclusion. 
The reference lists of the studies identified for inclusion were screened in an 
attempt to highlight any additional studies not discovered in the search of 
electronic databases. On this occasion no additional studies were identified. 
A summary table of the remaining seven studies can be found in appendix B. 
 
2.3 Systematic review of Randomised Controlled Trials 
In the absence of an existing systematic review of RCTs, a Cochrane review of 
randomised controlled trials was initiated and the protocol stage completed 
(Appendix C). This proceeded after completion of appropriate training and with 
the support of the Cochrane wounds group. None of the 170 RCT’s returned in 
search results met inclusion criteria for the systematic review; a strong indicator 
of the need for further research in this field. 
 
2.4 Literature reviews 
Two published literature reviews were identified; extracorporeal shock wave 
therapy for wound healing: Technology, mechanisms, and clinical efficacy 
(Mittermayr, Antonic et al. 2012) and Shock Wave Therapy in Wound Healing 
(Qureshi, Ross et al. 2011). Between the two reviews ten studies are included of 
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varied design investigating the efficacy of ECSW in the treatment of soft tissue 
wounds. Only two of the included studies feature venous ulceration in their 
sample; both studies are discussed in each literature review. 
Both literature reviews fail to distinguish results by wound type other than to state 
that venous ulceration represented the wound type with lowest healing rates (33% 
compared to at least 66% in all other wound types). Many defining factors are 
absent from both reviews; time to complete healing, study duration and 
concomitant treatment are all missing from discussion. One shared conclusion 
identifies smaller wounds (≤10cm2) of shorter duration (≤1 month old) as most 
likely to achieve complete healing. Neither literature review includes discussion of 
statistical analysis. 
Both literature reviews identify ECSW as a safe treatment modality with potential 
in the treatment of soft tissue wounds. The lack of study specific information and 
the non-systematic approach to review, make it impossible to extrapolate 
conclusions from these literature reviews about the effectiveness of the treatment 
in the management of venous ulceration, though it appears healing rates in excess 
of one third may have been achieved. The validity of these findings and any 
potential bias is difficult to ascertain. 
Both reviews recommend further study of the treatment for specific wound types 
in order to better define subsets of patients who may benefit the most. 
 
2.5 Non-randomised trials and studies  
Two prospective studies and a third retrospective study were identified as stand-
alone studies within the literature search. 
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Of the three studies, two directly address the effectiveness of ECSW in the 
treatment of soft tissue wounds, including wounds of venous aetiology. The third 
paper is primarily concerned with the influence of wound aetiology and 
comorbidity upon the success of ECSW in the soft tissue wound context. 
Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds: A Feasibility 
Study (Schaden, Thiele et al. 2007), is considered the seminal work in this area. 
It is certainly the first report of ECSW’s potential to aid the healing of soft tissue 
wounds. This non-randomised study includes 208 participants with complicated, 
non-healing wounds of varying origin. Venous ulceration accounts for 12% (25 
wounds) of the studied wounds. Within this group, mean baseline wound area was 
10.3cm2, an average of 3.7 sessions were administered with 60 day follow up. 
Treatment was delivered either weekly or fortnightly; amount of shock wave 
administered varied dependent upon wound area. Unfocused, electrohydraulic 
shock waves, with an energy flux density of 0.1mJ/mm2 were utilised in treatment. 
Primary outcome measure is complete wound healing with analysis of factors 
indicating likelihood of success. 
36% of the venous ulcers studied are reported to have healed in a mean of 43.5 
days. Multivariate logistic regression analysis showed significant difference in 
success of treatment based upon wound aetiology, with venous and arterial 
insufficiency indicating least positive outcomes. Wound size and duration emerged 
as predictors of wound healing; wounds of baseline area ≤10cm2 and of duration 
≤1 month were found to be statistically more likely to respond to treatment. It is 
further suggested that emphasis be placed upon the impact of wound duration, 
with wounds ≥10cm2 of duration ≤1 month also showing good response rate; 
essentially acute wounds showed greater response than chronic wounds. 
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Improved patient experience of wound pain and a reduction of wound exudate is 
demonstrated through further statistical analysis of data, though there is no report 
of the scale or method by which these outcomes were measured and no greater 
or more detailed measure of QOL is utilised. 
Very little detail is presented regarding concomitant treatment and historical 
treatment; combined with a lack of control group, this may limit the validity of 
results. By the authors own admission, there is a risk of bias whereby the 
increased wound care and debridement as a result of the study conditions may 
have contributed to positive outcomes, potentially perceived as attributable to the 
new intervention. Without control group or separate study arm for comparison it 
is difficult to know how this risk could have been reduced. 
The second study, Extracorporeal Shock Wave Therapy for the Management of 
Chronic Ulcers in the Lower Extremities (Saggini, Figus et al. 2008), addresses 
this issue in the design of a non-randomised controlled study whereby 30 
participants were recruited and treated with ECSW and a further 10 participants 
entered into a control group treated with regular, conservative dressings. Venous 
ulceration accounts for 40% (11 wounds) of the treatment group and 50% (5 
wounds) of the control group. 
Baseline wound area data is only presented for the responding wound group and 
ranges from 1cm2 to 9.7cm2. A minimum of 4 and a maximum of 10 treatment 
sessions were given; no follow up period is reported. 
Treatment was delivered every two weeks; amount of shock wave administered 
was calculated as 100 pulses per cm2 of wound area. Electrohydraulic shock 
waves, with an energy flux density of 0.037mJ/mm2 were utilised in treatment; it 
is unclear whether shock waves were focused or unfocused. Complete wound 
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healing is the main outcome measure with consideration given to impact upon 
participant experience of wound pain and exudate levels. 
There appears to be a discrepancy between the number of participants recruited 
with venous ulceration (12 wounds) and the number reported within the results 
section (11 wounds). Though no explanation is given, it is possible this participant 
was lost to follow up or excluded for some other reason. Within the treatment 
group, 36% of the venous ulcers are reported to have healed by end of study, no 
time period to primary outcome is presented. In the remaining venous ulcers, 
reductions of wound surface area are observed at between 32 and 70%. In 
comparison, none of the venous ulcers in the control group had healed by end of 
study. Furthermore, statistical analysis showed significant difference in the wound 
area reductions from baseline to final measurement in the ECSW group and no 
statistical significance in the control group. 
A substantial decrease in wound exudate is reported for all wounds in the 
treatment group, though little data is actually presented. Pain was evaluated 
utilising a numeric box scale (NBS); 80% of participants within the treatment 
group reported a 1 – 3 point decrease in pain score over the study period. Similar 
data is not presented for the control group, however it is stated that no statistical 
significance was shown in NBS scores for the control group. Beyond the reporting 
of exudate and pain data, no further measure of QOL is included. 
No information is included regarding concomitant treatment or the nature of 
conservative dressing utilised within the control group. Though the overall sample 
size is acceptable for a study of this type, the sub group of interest (venous 
ulceration) is small at 11 wounds of which only 4 achieved complete wound 
healing, making generalisation difficult. 
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The final study identified, The Influence of Comorbidities and Etiologies on the 
Success of Extracorporeal Shock Wave Therapy for Chronic Soft Tissue Wounds: 
Midterm Results (Wolff, Wibmer et al. 2011), retrospectively utilises the data set 
collected in Schaden et al’s initial 2007 paper. The focus of this new paper is to 
determine what influence existing comorbidities and wound aetiologies had upon 
the success rate of ECSW in the treatment of soft tissue wounds. Follow up 
appears to have been extended from the original study to a mean of 31.8 months, 
during which time it is reported that no wound recurrence occurred where 
complete healing had occurred. Further multivariate logistic regression analysis is 
undertaken to identify positive or negative factors influencing the success of 
ECSW. The authors conclude that existing comorbidities and wound aetiology have 
no statistically significant influence upon the effect of ECSW therapy in the healing 
of soft tissue wounds. As the data set is taken from the original 2007 study, the 
same limitations affect the outcomes of this paper. 
The lack of detail with regards concomitant treatment (wound dressings) in all 
three studies and varied, if not absent, follow up periods may limit the ability to 
compare outcomes with those reported for current best practice treatments. It 
may not be feasible to make comparisons in this way; as both primary studies 
point out, the wounds considered for advanced wound care techniques tend to be 
those which have failed to heal or improve via conventional treatment. These hard 
to heal wounds may not ever achieve rates of healing equal to those reported for 
treatments such as multilayer compression therapy. In such case, the reported 
36% of venous ulcers healed in both studies discussed here may be more 
impressive than first appears. 
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2.6 Case reports 
In 2013, (Stieger, Schmid et al. 2013) reported a single case study of ECSW 
utilised in the treatment of a 56 year old female patient suffering from chronic 
lower limb venous ulceration of duration at least six years. Aetiology had been 
confirmed by way of duplex ultrasound and surgical stripping of the incompetent 
great saphenous vein undertaken some eight years previous. Regular surgical 
debridement, compression bandaging, vacuum therapy and a variety of wound 
dressings had failed to aid wound healing. ECSW was undertaken alongside 
compression bandaging and a simple hydrofibre primary dressing; treatment was 
given weekly for a total of 30 sessions. Baseline wound area was 200cm2; 2000 
pulses of shock wave energy were administered at each session utilising an energy 
flux density of 0.25mJ/mm2. Complete wound healing was achieved at 30 weeks. 
There is no assessment of pain, exudate or any QOL measure. No follow up period 
is reported, though one episode of ulcer recurrence is described which was treated 
successfully at an early stage. 
A case of multiple, bilateral venous ulceration treated with ECSW was reported in 
2012 by (Fioramonti, Onesti et al. 2012). The 63 year old female patient suffered 
with two ulcers to the right leg (baseline area 1.5x2cm2 and 4x2cm2) and one 
ulcer to the left leg (baseline area 4x1.5cm2). Both ulcers on the right were treated 
weekly with ECSW for a total of six sessions; it is unknown whether shock waves 
were focused or unfocused. 100 pulses per cm2 of shock wave energy were 
administered utilising an energy flux density of 0.037mJ/mm2. The ulcer situated 
on the left leg was treated conservatively and without ECSW. Complete wound 
healing occurred in both ulcers situated on the right leg at six weeks, whilst the 
conservatively treated ulcer on the left leg remained unhealed. 
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As with the previous case report, no assessment of pain, exudate or any QOL 
measure is undertaken. No follow up period or incidence of recurrence is reported. 
2.7 Conclusion 
Overall, the evidence supporting ECSW in the treatment of venous ulceration 
appears positive. Though a very limited number of clinical studies were identified 
which included venous ulceration in their cohort, positive outcomes were reported 
including complete wound healing in around a third of patients, improved healing 
rates and reductions in pain and exudates. The validity of results from both clinical 
studies and case reports could be questioned; detail of methods and measures 
employed in the collection of data is universally lacking. The percentage of each 
studies sample focusing upon venous ulceration was small, making generalisation 
difficult. Furthermore, the majority of studies and cases reviewed have been 
designed without a control group. In such cases comparison to historic controls, 
whereby the effect of the intervention is compared to previous treatment 
outcomes can be utilised; the studies reviewed here pay little reference to 
historical or indeed concomitant treatments. Validated QOL measurement would 
have added much value to the outcomes of the reviewed studies and it is 
unfortunate that they were not included. There are no reports of adverse events 
in any study; the treatment would appear to be a safe, viable treatment option. 
Study authors have identified that their samples represent hard to heal wounds 
where conventional or accepted best practice techniques have failed to heal or 
improve a chronic wound. It seems imperative that results be considered in this 
context and not directly compared to the outcomes of current best practice; for 
example, multilayer compression therapy. Though healing rates of around 70% at 
six months have been demonstrated with multilayer compression therapy, what 
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is effectively being reported within the reviewed ECSW studies are samples taken 
from the remaining 30% of un-responding, hard to heal wounds. The 
generalisability of these results to the majority of patients with venous ulceration 
is unclear. 
Currently the role of ECSW as a primary treatment or adjuvant to best practice in 
routine care is unclear and requires assessment. Generally positive outcomes and 
the absence of adverse events suggest a study focusing upon venous ulceration 
alone would be justifiable. Poor reporting of study methodology is detrimental to 
the validity of the existing knowledge base. Prospective studies focusing upon the 
treatment of venous ulceration should be of clear technique and design; this would 
ideally include concomitant use of current best practice treatment, multilayer 
compression therapy. Patient related outcome measures (PROMs), specifically 
QOL assessment, are underreported and should not only be included, but 
prioritised in study design. 
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CHAPTER 3 - METHODOLOGY AND RESEARCH DESIGN 
3.1 Aims and outcome measures 
Primary aim: to assess the clinical effectiveness of ECSW in the healing and 
management of chronic venous ulceration, when combined with multilayer 
compression bandaging. 
Secondary aim: to assess the effect of ECSW on participant reported ulcer pain 
and exudate levels. 
To assess clinical effectiveness, the principal outcome measure was time to 
complete healing of the reference ulcer and improved QOL; secondary measures 
focused upon reduced pain scores, exudate levels and time to 50% reduction in 
ulcer area. In accord with quantitative methodology these outcome measures are 
reliant upon empirical observations, generating consistent numerical data (Ellis 
2013). These aims and core elements shape and inform the design of this 
prospective, quantitative study. 
In addition to the assessment of these clinical outcomes, this study also sought to 
evaluate the processes of the study itself. The purpose of which was to ascertain 
the validity of the methodology, methods and tools utilised in its execution. The 
outcome of such evaluation would be to help inform a further or greater study.  
 
3.2 Methodology 
The philosophical basis for the design of this study is firmly rooted in positivism, 
the belief that knowledge is derived from direct measurement or observation. The 
positivist approach to research generally dispels such notions as intuition and 
speculation, instead favouring practical results and empirical measurement, 
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aiming for a high degree of objectivity (Moule, Goodman 2009, Gerrish, Lacey 
2010). It is for these reasons that positivism is most associated with quantitative 
research methods and design, the basis and direction for the structure of this 
study (Parahoo 2006). 
Within the sphere of quantitative methodology, three main concepts of research 
design are most often described: experimental, non-experimental and quasi-
experimental (Burns, Grove et al. 2011, Boswell, Cannon 2014). Historically, 
literature describing health care research methodology and design has promoted 
experimental designs, namely clinical trials and randomised controlled trials 
(RCT), as the gold standard of healthcare research (Cormack 2000, Crookes, 
Davies 2004). When considering an appropriate research design for this study 
several issues render purely experimental designs implausible; the foremost of 
these issues is the need for substantiative, supporting evidence to justify the 
requirement for a randomised controlled trial (Bassett 2001). It has been 
established through literature review that the incidence of venous ulceration 
examined within ECSW studies is unsatisfactory to fully inform practitioners of its 
effectiveness in the treatment of this condition. This lack of underpinning 
knowledge would be detrimental to the external validity of an experimental 
design; without systematic review of known outcome measures, the sample size 
required to generalise the results of a randomised controlled trial could not be 
calculated (Watson 2008, Dekkers, von Elm et al. 2010). It is therefore 
appropriate in this situation to consider the structuring of a pilot or feasibility study 
utilising a non-experimental or quasi-experimental design. 
The terms pilot and feasibility are often used interchangeably, are reported poorly 
and have traditionally received little attention within research methodology 
 29 
 
textbooks (Gardner, Gardner et al. 2003). Several studies have sought to better 
define these terms and the expectations of their purpose. 
Feasibility studies appear to be best defined as exploratory pieces of work 
preceding the design of a main study; outcomes focus upon the estimation of 
parameters key to the main studies design such as standard deviation of outcomes 
to calculate the main studies required sample size. Crucially, feasibility studies do 
not evaluate the outcome of interest, which in this case would be the effectiveness 
of a clinical intervention (Bowen, Kreuter et al. 2009, Arain, Campbell et al. 2010). 
Pilot studies are also exploratory in nature and focus upon the evaluation of 
components of research design prior to the event of a main trial or study 
(Lancaster, Dodd et al. 2004, Leon, Davis et al. 2011). It is most likely for these 
reasons that the terms pilot and feasibility are often wrongly interchanged. The 
pilot study is best described as a smaller scale version of the main study, 
evaluating how study components such as recruitment or data collection tools 
perform. An interesting feature of the pilot study is that data evaluating the 
outcome measure of interest can contribute to the outcomes of the main study, 
this has been referred to as an internal pilot study. Adversely this same data can 
be analysed and presented of its own accord independently of the main study, 
often described as an external pilot (Hertzog 2008, Arain, Campbell et al. 2010). 
Research of Non-experimental or Quasi-experimental design is often described as 
a weaker source of evidence, suffering from greater confounding factors which are 
detrimental to the internal validity of a study (von Elm, Altman et al. 2007). Bias 
in participant selection, group allocation and study performance appear to be the 
foremost reported concerns. These risks are greatly reduced in experimental 
design through the process of randomisation and control (Maltby 2010, Newell, 
Burnard 2011). 
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Yet studies of this type have a place in research design and are credible sources 
of knowledge indicative of real world, daily practice (Papanikolaou, Christidi et al. 
2006). Quasi-experimental studies can allow conclusions to be drawn about the 
effectiveness of an intervention without the requisite randomisation of participants 
to control groups; the effect of the independent variable can be observed in a 
more natural setting (Ellis 2013, Jolley 2013). Various methods of statistical 
analysis can be employed to combat the problems associated with a lack of 
randomisation (Newell, Burnard 2011). 
One applicable model is a before-after design; a quasi-experimental strategy 
which can produce reliable data by controlling threats to internal validity (Glass 
2008, Polit, Beck 2012). A before-after design can employ a control group or 
function with the intervention group alone. When a separate control group is not 
utilised, pre intervention followed by multiple post intervention measurements can 
increase confidence in study results. It is generally understood that not utilising a 
control group puts at risk the internal validity of a study. 
This prospective pilot study utilises a before-after design without a control group; 
the multiple observations required should reduce the chance of mistaken 
conclusions and allow detailed analysis of outcome data and trends (Anderson 
2011).  
 
3.2.1 Population and sampling 
The target population from which this study’s sample is chosen are those affected 
by chronic venous ulceration; specific inclusion and exclusion criteria are used to 
further refine this group (Boswell, Cannon 2014). From the target population, the 
goal within quantitative research is to choose a sample which contains participants 
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whose characteristics can be said to generalise to the wider target population (Gill 
2010); various sampling techniques can aid in this process. 
Probability sampling, most often divided into random and cluster sampling 
techniques, appear to be regarded as the preferred strategies in quantitative 
research (Crookes, Davies 2004, Matthews, Kostelis 2011). This is primarily due 
to their ability to consistently produce a highly representative sample; they do 
however tend to require sizable accessible populations, often only attainable over 
longer periods of time (Polit, Beck 2013). 
Non-probability sampling is widely described in literature as being unable to 
produce samples from which data can be generalised into the target population 
(Parahoo 2006). Yet this appears to present a dichotomy, as non-probability 
strategies are utilised frequently in research design, particularly in exploratory 
studies where underpinning knowledge or previous research is limited. The 
consideration of practicality is also of great importance; limitations of time and 
resource, including financial, are cited as valid reasons to pursue non-probability 
sampling strategies (Newell, Burnard 2011). 
A convenience sample, whereby those selected for inclusion are taken from the 
easiest, most direct source without any form of subjective input, could have been 
employed (Burns, Grove et al. 2011). However, homogenous sampling allows the 
selection of a sample in which very specific characteristics are shared amongst the 
participants. Though this could be perceived as a limitation to the generalisation 
of results, it creates a sample of particular interest, best placed to answer the 
research question in this small, prospective study (Polit, Beck 2013, Crookes, 
Davies 2004). 
The size of the prospective sample should be of an appropriate volume to 
sufficiently achieve the study aims, normally to demonstrate a difference or 
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similarity between groups of data (Cormack 2000). As a general rule, larger 
sample sizes have a higher chance of detecting a difference or similarity between 
groups of data (Newell, Burnard 2011). This is not to say that sample sizes should 
always be large, or larger than required; an excessive sample size may be 
inappropriate, wasteful of resources or be unethical. Interestingly, the estimate of 
sample size has been described as being at worst, a well educated guess and 
seems to hinge upon the estimation of size of effect, underpinned by clinical 
judgement (Whitley, Ball 2002).  
The concept of effect size examines the extent of the relationship between two 
variables, quantifying the strength of the trend to be generalised to the wider 
population. If the size of the effect is large, it should be easier to detect and thus 
require a smaller sample size (Watson 2008). Though drawing from small samples, 
reviewed studies showed good effect size in analysis of results; a similar, 
moderate to small sample size in this prospective study should be equally capable 
of demonstrating treatment effect. 
 
3.2.2 Data collection and analysis 
It is of the utmost importance that the data collected from the sample answers 
the research question, achieving the specified objective. The use of existing, 
validated tools such as surveys and established scoring mechanisms can assist 
robust collection of data in quantitative studies (Moule, Goodman 2009). The core 
of data required to fulfil the aims of this study requires the collection of 
biophysiological data; not involving the taking of materials for laboratory analysis, 
such as blood or tissue samples, but the systematic measurement of a condition’s 
specific symptoms in situ (Boswell, Cannon 2014). 
 33 
 
The types of data collected in quantitative research appears to be most simply 
described as discrete or continuous (Gerrish, Lacey 2010). This study makes use 
of both discrete data, wherein numerical data is collected but is only measured in 
terms of whole numbers and continuous data featuring information of any 
numerical value within a particular range (Fitzpatrick, Wallace 2006). 
The numerical data generated in this, and indeed any, quantitative study falls 
within the conventional measurement scales of nominal, ordinal, interval or ratio 
scales (Maltby 2010). Data collected utilising an ordinal scale of measurement is 
generated via externally validated QOL surveys utilising ranked order responses 
(Martin, Thompson 2000). Reported pain experience is also quantified using 
another example of ordinal measurement, visual analogue scores (VAS); making 
use of a low to high numerical score that does not rely upon an equally spaced 
measure, such as the measure of length or time which are examples often cited 
in the discussion of interval or ratio measurement scales (Parahoo 2006, 
Hjermstad, Fayers et al. 2011). 
Within this pilot study ratio measurement scales, specifically the measurement of 
wound area, will be utilised in the collection of wound measurement data. These 
measurements differ from interval measurement scales, as a measurement of zero 
area will indicate the complete absence of a measurable wound (Pedhazur, 
Schmelkin 2013). 
Quantitative data of the type discussed can be analysed at various statistical 
levels; most commonly, descriptive statistics and inferential statistics are utilised 
(Riffenburgh 2012). The function of descriptive statistical analysis is to summarise 
the data collected from the study sample in terms of averages, or central tendency 
and the reporting of variance, including standard deviation (Watson 2008). These 
summaries refer only to the study’s sample, unlike the use of inferential statistical 
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analysis, the goal of which is to draw conclusion from the data collected which 
may be generalised to the wider population (Peat, Barton 2005, Riffenburgh 
2012). Specific statistical models are utilised to demonstrate degrees of 
confidence in the drawn conclusions and statistical significance. Both descriptive 
and inferential analysis was employed in the examination of study data. 
 
3.2.3 Ethical considerations 
In consideration of ethical implications and the research process, many factors 
must be taken into account to safeguard both participant and researcher. Fidelity, 
veracity and justice are three closely related ethical principles concerned with the 
fair treatment and safeguarding of participants (Cormack 2000). Within this study 
the fair and ethical treatment of all participants was ensured through honesty and 
transparency, whereby participant’s welfare was paramount, though it may be 
detrimental to the objectives or completion of the study. 
The principal of non-maleficence, whereby no intentional harm should come upon 
participants was diligently observed; had any sign of potential harm or risk of 
harm occurred during the study it would have been reported accordingly after 
cessation of treatment (Burns, Grove et al. 2011). 
 
3.3 Study methods and procedures 
For the purposes of this pilot study a chronic venous leg ulcer was defined as an 
open lesion between the knee and ankle joint that has remained unhealed for at 
least four weeks and has occurred in the presence of clinical signs of venous 
disease (SIGN 2010). These include: haemosiderosis, lipodermatosclerosis, 
 35 
 
oedema, eczema, malleolar flare, atrophie blanche, stigmata of previous venous 
ulceration, and/or varicose veins (Smith 2006).  
Participants may have had more than one ulcer, situated on one or both legs. A 
single, reference ulcer was selected for treatment; this was the ulcer thought most 
likely to be the slowest healing. This judgement was based upon its size, duration 
or appearance. In participants with multiple ulcers, where the reference ulcer only 
was treated with ECSW, the secondary ulcers were also measured and rate of 
healing determined for comparison. 
 
3.3.1 Inclusion and exclusion criteria 
Table 3 – Inclusion and exclusion criteria 
 
Inclusion criteria 
• The presence of leg ulceration assessed to be due to underlying 
venous insufficiency 
• The reference ulcer must be in excess of area 1cm2 
• The reference ulcer must have persisted despite at least 6 weeks of 
treatment with multilayer compression bandaging 
Exclusion criteria 
• ABI pressures less than 0.8 
• Participants with known rheumatoid arthritis or systemic vasculitis  
• Participants with diabetes 
• Suspicion of malignancy or known malignancy within the ulcer 
• Acute Deep vein thrombosis 
• Age less than 18 years 
• Life expectancy of less than 1 year 
• Allergy to compression bandaging materials 
• Participants unable to tolerate multilayer compression therapy 
• The participant is unable to speak/understand English 
• Inability to give informed consent 
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3.3.2 Recruitment 
In the recruitment of a sample, a homogenous sampling strategy utilising strict 
inclusion and exclusion criteria (Table 3) was been used to select participants from 
the available population. This consisted of participants recruited from hospital 
wards, out-patient and community clinics. 
This study sought to compare reported ulcer healing rates in participants who have 
undergone standard compression therapy, with the healing rate data collected 
from participants undergoing ECSW combined with standard therapy. Therefore in 
the consideration of sample size, estimating size of effect should also draw upon 
the outcomes of systematically reviewed literature pertaining to compression 
therapy for venous ulceration. 
The largest systematic review of this kind was published by The Cochrane 
Collaboration (Cullum, Nelson et al. 2002) and was most recently updated in 2013. 
Of the forty-eight RCTs included, 40% had sample sizes of 50 or fewer 
participants, 67% recruited 100 or less participants. From within the review, eight 
RCTs specifically question the effectiveness of compression therapy in the healing 
of venous ulcers; these studies most closely resemble the aim of this before-after 
study. Sample sizes vary, with a median average of 51 participants (SD=79), 
relatively small but justified due to the large size of effect reported. It was 
therefore estimated that a sample size of 40 participants was reasonable for this 
non randomised study. 
Participants were screened for eligibility and potential participants assessed to be 
eligible were issued with the participant information sheet and the study explained 
in detail. Following this, participants were given time (a minimum of 24 hours) to 
reflect and discuss with family and friends before being asked to sign the study 
consent form. Permission was obtained to inform the participant’s GP by letter of 
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their involvement in the study. Once recruited, participants were free to withdraw 
should they have wished at any stage. On entry into the study participants were 
given a unique identification number, used throughout the study. Example 
participant documentation from this recruitment stage can be found under 
appendix D. 
 
3.3.3 Collection of study data 
Participants were asked to attend an initial, pre-treatment research clinic 
appointment. A concise medical history was taken, assessing comorbidities, 
current medication, allergies and mobility. Body Mass Index (BMI) was calculated 
and recorded in order to categorise participants weight; the most commonly 
accepted ranges were utilised whereby a BMI of <18.5 is considered underweight, 
18.5 to 25 normal weight, 25 to 30 overweight and >30 considered obese (World 
Health Organization 2006).  
A specific history of the current episode of ulceration including duration, number 
of previous episodes and previous clinical treatments was also taken. Ulcer 
aetiology was confirmed by ABI and by analysis of duplex ultrasound imaging. 
Participants were also screened for the presence of varicose veins; if present CEAP 
classification and the venous clinical severity score was used to assess 
(Rutherford, Padberg Jr et al. 2000, Eklöf, Rutherford et al. 2004). 
Ulcer assessment began by recording the number of ulcers present and their 
position drawn on a leg diagram. The reference ulcer was clearly identified and all 
ulcers assigned a number. Concise ratio scale measurements, relating to each 
ulcer, were collected in several ways including serial measurement of the surface 
area of each ulcer, used as an index of healing and performed by tracing the 
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margins at each clinic appointment. Traditionally performed manually, utilising 
tracing paper and pen this method of wound area measurement can be inaccurate, 
invasive and difficult to reproduce. Within this study, wound margin tracings were 
made utilising three dimensional (3D) digital imaging software, a system which 
has been shown to produce extremely accurate, repeatable wound measurements 
which include both wound area and volume (Bowling, King et al. 2009, Savage, 
Jeffery 2013).  
Ordinal scale measurement, in the form of visual analogue scores (VAS) were used 
to collect data pertaining to participants experience of pain in relation to their 
ulceration. Wound exudates were recorded using a low, medium, high scale. All 
baseline data was recorded on a customised data collection form (Appendix E). 
QOL was assessed by collecting data from each participant through the completion 
of the disease specific, Charing Cross Venous Ulcer Questionnaire (CXVUQ) and 
generic QOL of life SF-36 and EQ-5D questionnaires, all of which are recognised, 
externally validated data collection tools based upon ordinal measurement scales 
(Ware Jr, Gandek 1998, Smith, Guest et al. 2000). These questionnaires were 
completed by participants at every research clinic appointment. 
The CXVUQ consists of 20 disease specific questions scored on a 1 to 5 point Likert 
scale; lower scores indicate better QOL of life (Wong, Lee et al. 2006). In 2007 an 
error in the CXVUQ scoring system was reported whereby questions 3 and 7 of 
the original publication had been incorrectly scaled (Jull, Parag 2007). In this study 
all CXVUQ data was corrected for this error. As a disease specific questionnaire, 
less literature is available describing the CXVUQ than for generic QOL 
measurement tools. There appears to be scant if any information available 
regarding Minimally Important Differences (MID) for CXVUQ scores. Most studies 
seem therefore to focus upon statistical rather than clinical significance in 
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discussion of changes in score (González‐Consuegra, Verdú 2011, Jull, Parag et 
al. 2010) 
SF-36 QOL questionnaire responses are scored over 8 domains; these domains 
combine to give additional physical and mental component scores. All scores 
operate on a scale of 0 to 100, with higher scores indicating greater QOL (Patel, 
Donegan et al. 2007). Many studies have discussed the MID required to constitute 
a significant clinical change in SF-36 composite scores, with estimates ranging 
from a change of 5 to 10 points; much unresolved debate appears to exist 
regarding variability of SF-36 MID dependent upon the condition being studied 
(Walters, Brazier 2003, Bjorner, Wallenstein et al. 2007). 
The EQ-5D questionnaire is somewhat different; a simple tool consisting of 5 
questions plus a visual analogue score defines health in terms of mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. An index score 
ranging from 0.0 to 1.0 is generated from responses, higher index values indicate 
greater QOL (Rabin, Charro 2001). Based upon the UK data set, the MID required 
to constitute a clinically significant change in EQ-5D score has been reported as 
between 0.08 and 0.10; it is important to note that EQ-5D MID outcomes were 
primarily drawn from studies examining conditions other than venous ulceration 
(Walters, Brazier 2005, Pickard, Neary et al. 2007). 
The data collected at the baseline assessment was treated as the pre-intervention 
data collection point in the before-after study design. Post baseline assessment, 
each participant received an initial course of ECSW treatments. These treatments 
were structured as three sessions delivered at fortnightly intervals. If the ulcer 
area or volume reduced after the third initial treatment session but had not 
achieved complete healing, a further course of three treatment sessions were 
administered over the same time structure. Treatment ceased at three months, 
 40 
 
after the maximum of six treatment sessions; participants were then followed up 
to 6 months and if their ulcer had not healed at that time they continued to receive 
routine NHS care and treatment. Treatment also ceased if, after three initial 
treatments the index ulcer was observed to deteriorate in relation to the primary 
outcome (increase of ulcer size/volume). Data was collected at each treatment 
session precisely mirroring the methods of measurement utilised at baseline data 
collection, this created a series of data to be viewed as the intervention stage of 
the before-after design (Figure 3). 
 
Figure 2 – Before-after design 
 
 
If the ulcer healed during the treatment or follow up period, a digital photograph 
of the index ulcer was taken, this image was then analysed by two blinded 
assessors. If all of the assessors agreed that the ulcer had healed, then the 
participant was treated as a healed ulcer and followed up as planned. If the ulcer 
reoccurred, the participant was asked to contact the research team. If any 
assessor felt that the ulcer was yet to heal, but that healing would probably occur 
in the next few weeks; weekly photographs were taken until a consensus was 
reached that the ulcer had healed. 
Clinical data was entered into a study database; range and consistency checks 
were incorporated into the database and an audit of a random 5% of entries 
performed to assess errors. If a greater than 5% error rate was obtained then all 
entries were rechecked. Data collected during the course of the research was kept 
Week 1 Week 12 Week 24
Pre Treatment Treatment 1 Treatment 2 Treatment 3 Treatment 4 Treatment 5 Treatment 6 Post Treatment
Baseline Follow-upIntervention
Week 6
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strictly confidential and accessed only by members of the study team. Participant’s 
personal details were stored on paper format only. 
 
3.3.4 Intervention, wound care and compression 
Participants received ECSW routinely every two weeks in an outpatient clinic 
setting to the reference ulcer only, under no aesthesia. Ultrasound gel was applied 
directly to the wound bed and the shock wave applicator to aid conduction of shock 
wave pulses; the ulcerated area was covered with a sterile cellulose barrier. 
Electrohydraulic shock waves were generated by an MTS Dermagold 100 and 
applied evenly to the ulcer surface. Each shock wave impulse delivered 
0.10mJ/mm2 energy flux density at a frequency of 5Hz. Quantity of impulses to 
be delivered were calculated thus: wound area x20 + minimum application of 350 
pulses = total shockwave pulses. 
A standard wound care regime was maintained throughout treatment and at home 
between sessions, including wound cleansing with sterile normal saline solution. 
The wound dressing consisted of a non-adherent mesh dressing, a hydrofibre 
agent and an absorbent layer; dressings were changed at a minimum period of 
weekly. Multilayer compression bandaging, already utilised pre study enrolment, 
continued after assessment of ankle brachial pressures, in accordance with 
national guidelines (SIGN 2010). The presence of clinical features of infection 
resulted in clinical review and antibiotic treatment if required. As per current 
national guidelines all participants received multilayer compression therapy, with 
the aim of applying 35-40mmHg pressure at the ankle. 
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3.3.5 Mode of data analysis 
All study data was entered into the statistical package software, SPSS version 22 
for analysis. Nominal and ordinal data values were given specific labels to help 
identify variables in the analysis process. The process of cleaning the dataset was 
performed in order to identify missing data and potential errors. Consistency 
checks were performed on the completed dataset and an audit of a random 5% of 
entries performed to assess errors. If a greater than 5% error rate had been found 
then all entries would have been rechecked. 
Missing value analysis was performed to identify number and location of missing 
values for each variable. The pattern of missing values was also assessed to 
identify specific areas of incomplete data entry. 
The discrete and continuous data generated in this study has been analysed using 
both descriptive and inferential statistical methods (Maltby 2010). Descriptive 
statistics were utilised to summarise all of the sample specific data, illustrating 
trends in terms of central tendency, averages and variance. 
The distribution of continuous data was examined using the Shapiro-Wilk test of 
normality (Petrie, Sabin 2013). The dataset was mainly found to be not normally 
distributed (p<0.001), except for QOL data which fell within normal distribution 
(p>0.05). 
Statistical tests of probability were utilised to infer generalisations to the wider 
population from the sample data. For data not normally distributed these included 
non-parametric tests such as the Wilcoxon signed ranks test and Friedman test. 
For normally distributed data, parametric versions of these tests were utilised 
including repeat measures ANOVA and paired samples t-test. The use of these 
statistical tests allowed analysis of baseline to follow up and between measures 
data (Hampton, Havel 2006, Petrie, Sabin 2013). 
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Other statistical tests utilised included Kaplan-Meir survival curves examining time 
to healing data and McNemar-Bowkers test, used to examine differences in 
variance of certain categorical data. Fisher’s exact test was used to examine the 
relationship between baseline characteristics and wound healing outcomes 
(Anthony 1999, McKillup 2011). 
 
3.3.6 Missing data 
44 missing values were identified throughout the dataset, accounting for only 
2.7% of data content. Pattern analysis showed a small amount of random missing 
data. Given the small size of the study sample, much consideration was given to 
the treatment of missing data. The simplest approach would have been to omit 
cases containing missing data, often referred to as listwise deletion or complete 
case analysis (Munro 2005). The impact this would have had upon an already 
small sample size would have been detrimental to analysis and appears an 
excessive solution given the overall small quantity of missing values. 
Multiple imputation analysis was considered and certainly has some attractive 
qualities in terms of producing viable missing data substitutions. However, it is a 
more complicated method which can impact or restrict further statistical analysis 
of the resultant dataset (Schafer, Olsen 1998, Wayman 2003). Given the small 
quantity of missing values, this method was rejected in favour of stochastic 
regression imputation. This form of imputation utilises existing variables to predict 
the missing value whilst maintaining a degree of random error to each imputed 
value (Baraldi, Enders 2010). Consistency checks were repeated to ensure the 
validity of imputed data values. 
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3.3.7 Ethics and safety 
Ethical approval was sought from the local National Research Ethics Service 
(NRES) and upon first submission, was declined. The NRES committee cited 
concerns regarding the robustness of the study design and a potential conflict of 
interest where the researcher was involved in the delivery of treatment. After 
review and revision, application was resubmitted and a favourable ethical opinion 
was given by the committee; further ethical approval was then granted from The 
Robert Gordon University and the local NHS Research and Development 
department. Documentation relating to ethical approval can be found under 
appendix F. 
With regards consent and confidentiality, the purpose of the research, its format 
and an explanation of the treatment was discussed with potential participants at 
an initial research clinic appointment. Written information (Appendix D) was also 
given and participants received ample time (a minimum of 24 hours) to reflect 
before signing a written consent form (Appendix D). In gaining written consent 
the following conditions had to be satisfied. The person giving consent had to be 
deemed capable of doing so, the participant must have receive appropriate and 
adequate information, there is freedom of choice, the person giving consent 
should be aware that consent is an ongoing process and is able to withdraw 
consent (Bassett 2001). 
Data collected during the course of the research was kept strictly confidential and 
accessed only by members of the study team. Participant’s personal details were 
stored on paper format only and were not entered onto the study database. 
Participants were allocated an individual specific study number and this alone was 
used to identify their data. To comply with the 5th Principle of the Data Protection 
Act 1998, personal data will not be kept for longer than is required for the purpose 
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for which it has been acquired. Essential data shall be retained for a period of at 
least 10 years following close of study. 
Annual progress reports, safety reports and a final report at the conclusion of the 
study have been submitted to the Research Ethics Committee within the timelines 
defined in the regulations.   
 
3.3.8 Safety 
The study was subject to monitoring by the local NHS Research and Development 
department to ensure that it was being conducted as per protocol, adhering to 
Research Governance, Good Clinical Practice (GCP) and appropriate legislation. 
Monitoring feedback and correspondence can be found under appendix G. 
It was planned to record all adverse events via research follow-up visits at 6 
weeks, 3 months, and 6 months and at all ECSW treatment sessions. 
Adverse events were assessed in respect of severity, relationship to study 
treatment, whether expected or unexpected, duration and whether constituting a 
Serious Adverse Event (SAE). Non-serious events that are not pre-defined study 
outcomes were recorded. The following adverse events were expected: 
• Discomfort 
• Minor bleeding 
• Wound infection 
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CHAPTER 4 - FINDINGS 
4.1 Participant characteristics 
34 participants were screened for suitability; 28 met inclusion criteria and entered 
the study, 6 were excluded; this is illustrated in the CONSORT diagram (Figure 4). 
Demographics and baseline ulcer characteristics are summarised in table 4 and 5. 
The cohort consisted of 14 men and 14 women with a median age of 69 years 
(IQR=33). Median baseline ulcer area was 22.89cm2 (IQR=36.49), with a chronic 
duration of greater than six months in all but one participant. 
Figure 3 – CONSORT diagram 
 
 
 
 
 
 
 
 
 
 
   
*Remains healed at 6 months 
*Remains healed at 12 weeks 
Screened 
34 participants 
Excluded - 6 participants: 
5 arterial aetiology 
1 lymphedema 
Consented 
28 participants 
Initial course of 
3 treatments 
28 participants 
6 week clinical time point - 28 participants 
 
Healed 
1 participant* 
Unhealed 
24 participants 
≥50% reduction 
3 participants 
Additional course 
of 3 treatments 
27 participants 
 
Healed 
8 participants* 
Unhealed 
12 participants 
≥50% reduction 
8 participants 
Healed 
9 participants 
Unhealed 
7 participants 
≥50% reduction 
12 participants 
12 week clinical time point - 28 participants 
 
6 month follow up clinical time point - 28 participants 
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Table 4 - Participant demographics 
Characteristic N (%) 
Sex 
Male 
Female 
 
14 
14 
 
(50) 
(50) 
Age 
18-30 years 
31-50 years 
51-65 years 
Over 65 years 
 
0 
7 
4 
17 
 
(0) 
(25) 
(14) 
(61) 
 Comorbidities 
Ischemic heart disease 
Hypertension 
COPD 
Chronic Kidney Disease 
Previous IV drug misuse 
 
Patients with multiple comorbidities 
 
6 
7 
4 
4 
6 
 
9 
 
(21) 
(25) 
(14) 
(14) 
(21) 
 
(31) 
Body Mass Index 
Underweight 
Optimal 
Overweight 
Obese 
 
2 
5 
7 
14 
 
(7) 
(18) 
(25) 
(50) 
Mobility 
Fully mobile 
Requires assistance to mobilise 
Immobile 
 
15 
8 
5 
 
(54) 
(28) 
(18) 
Venous history 
Previous venous surgery 
Previous deep vein thrombosis 
 
2 
9 
 
(7) 
(31) 
 
Table 5 - Baseline ulcer characteristics 
Characteristic N (%) 
Index ulcer - surface area 
Area < 5cm2 
Area 5-20cm2 
Area 21-50cm2 
Area > 50cm2 
 
4 
8 
12 
4 
 
(14) 
(28) 
(44) 
(14) 
Affected limb 
Bilateral 
Left leg only 
Right leg only 
 
3 
12 
13 
 
(11) 
(43) 
(46) 
Current ulcer episode duration 
< 6 months 
6-20 months 
21-50 months 
> 50 months 
 
1 
19 
7 
1 
 
(3) 
(69) 
(25) 
(3) 
Ulcer history 
One occurrence (current) 
Recurrent episodes 
 
22 
6 
 
(79) 
(21) 
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4.2 Wound healing 
At 6 month follow up 9 participants index wounds had healed; a further 12 wounds 
had a reduction in surface area of ≥50%. 5 participant’s wounds achieved ≤50% 
area reduction; the surface area of 2 wounds remained unchanged from baseline. 
None of the studied wounds deteriorated. 
The median wound area for the cohort reduced from 22.89cm2 (IQR=36.49) at 
baseline to 6.50cm2 (IQR=19.26) at 6 month follow up, a statistically significant 
72% reduction (p<0.001), illustrated in figure 4. 
Analysis of the median wound area between each clinical time point and for each 
wound healing outcome (table 6), shows a statistically significant reduction 
between measurements for those who healed their wound (p<0.001) and for those 
achieving ≥50% reduction of surface area (p=0.004). 
 
Table 6 - Wound healing measurement results 
  
Outcome 
Median area (cm2) (IQR)  at each clinical time point Friedman test 
p value Baseline 6 weeks 12 weeks 6 months 
Healed 22.96 (39.44) 6.00 (4.75) 0 0 <0.001 
Reduced by ≥50% 9.99 (24.93) 8.82 (20.31) 10.99 (13.74) 6.50 (10.72) 0.004 
Reduced by ≤50% 41.94 (36.33) 35.20 (26.60) 34.36 (24.90) 33.06 (38.74) 0.692 
Total cohort 22.89 (36.45) 8.45 (28.78) 8.31 (23.88) 6.50 (19.26) <0.001 
Outcome 
Median area (cm2) (IQR)  at each clinical time point Wilcoxon test 
p value Baseline 6 months 
Total cohort 22.89 (36.45) 6.50 (19.26) <0.001 
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Figure 4 – Ulcer area at each clinical time point 
 
 
 
 
 
 
 
In participants who healed their ulcer, the median time to complete wound healing 
was 8 weeks (IQR=5) which involved 4 ECSW treatments. The median rate of 
healing was 1.91cm2 (IQR=2.77) per week. 
Wounds which achieved a ≥50% reduction of surface area did so in a median of 
10 weeks (IQR=17.5) which involved 5 ECSW treatments. The median rate of 
healing was 0.45cm2 (IQR=1.10) per week. 
Of the three participants with multiple ulcers, the index ulcer was unhealed at 6 
months. The rate of healing of the index ulcers treated with ECSW was median 
0.43cm2 (IQR=NA) per week; for secondary ulcers not treated with ECSW the 
median rate of healing was 0.09cm2 (IQR=NA) per week. 
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The proportion of the cohort achieving healed or ≥50% reduction of surface area 
outcomes at each clinical time point, as well as those remaining at risk, is 
illustrated by Kaplan Meir Survival Curves in figure 5. 
Wound healing outcome examples are illustrated in figures 6 and 7. 
 
Figure 5 – Kaplan Meir Survival Curve 
        
 
 
Remainder at risk at each clinical time point 
Outcome 
Clinical Time Point (weeks 
2 4 6 8 10 12 24 
Healed (n=9) 28 24 22 21 20 19 19 
≥50% reduction (n = 12) 28 27 25 23 21 20 16 
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Figure 6 – Wound healing examples – Participants achieving wound closure 
             
 Participant A: Baseline  6 weeks              12 weeks                       6 months 
             
Participant B: Baseline  6 weeks              12 weeks                        6 months 
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Figure 7 – Wound healing examples - ≥50% wound area reduction 
             
Participant C: Baseline  6 weeks              12 weeks                       6 months 
             
Participant D: Baseline  6 weeks              12 weeks                        6 months
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4.2.1 Baseline characteristics and wound healing outcome 
Baseline characteristics for each outcome measure are summarised in table 9. 
There was a tendency for median baseline ulcer area to be smaller in the healed 
group than in those achieving ≤50% area reduction (p>0.05). This is also true of 
the group achieving ≥50% reduction when compared to those achieving ≤50% 
area reduction (p>0.05). However, the relationship is unclear; those achieving 
≥50% reduction failed to completely heal despite having a smaller baseline ulcer 
area than the healed group. Similarly, baseline ulcer duration appeared shorter 
for the healed group than for those achieving ≤50% area reduction (p>0.05). This 
differs in the ≥50% reduction group which had a shorter baseline duration than 
the healed group, but failed to completely heal. 
Comparison of baseline median BMI shows those who healed their wound were 
closer to a healthy weight (BMI 18.5 to 25), whilst those in the ≥50% and ≤50% 
reduction group tended to be overweight (BMI 25 to 30) or obese (BMI >30) 
(p>0.05). 
Table 7 - Baseline characteristics and wound healing outcome 
Characteristic Healed N=9 ≥50% reduction N=12 ≤50% reduction N=7 
Male (N) (%) 6 (67) 4 (33) 4 (57) 
Female (N) (%) 3 (33) 8 (67) 3 (43) 
Median Age  (years) (IQR) 68 (26) 72 (36) 71 (39) 
Body Mass Index (BMI) (IQR) 25.90 (10.6) 30.00 (6.4) 30.00 (4.4) 
Baseline Ulcer Area (cm2) (IQR) 22.96 (39.44) 9.99 (24.93) 41.94 (36.33) 
Current Ulcer Duration (months) (IQR) 14 (28) 9 (11) 18 (17) 
Duration of Compression Use (months) (IQR) 8 (11) 7 (6) 8 (5) 
Previous Deep Vein Thrombosis (N) (%) 2 (22) 4 (33) 3 (43) 
Ischaemic Heart Disease (N) (%) 1 (11) 2 (17) 3 (43) 
History of Intravenous Drug Misuse (N) (%) 1 (11) 4 (33) 1 (14) 
Mobility    
Fully mobile (N) (%) 5 (55) 7 (58) 3 (43) 
Requires assistance to mobilise (N) (%) 3 (33) 3 (25) 2 (28) 
Immobile (N) (%) 1 (11) 2 (17) 2 (28) 
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4.2.2 Shock wave energy 
All wounds received 0.10mJ per mm2. The median shock wave energy delivered 
at each treatment is summarised in table 10. Healed wounds received total median 
energy of 211.50mJ (IQR=124.40), wounds achieving a ≥50% area reduction 
received 302.45mJ (IQR=236.90), wounds in the ≤50% area reduction group 
received 538.10mJ (IQR=733.80). 
Though no statistical difference was shown between the total median shock wave 
energy delivered to participants in any of the three outcome groups (p=0.411), 
there was a trend for higher energy values to be delivered to the ≤50% area 
reduction group compared to the healed and ≥50% reduction groups. 
 
Table 8 - Median total energy delivered at each treatment 
Treatment 
Median Energy (mJ) (IQR) 
Healed ≥50% reduction ≤50% reduction Total Cohort 
1 80.90 (79.00) 55.00 (50.00) 118.90 (73.00) 80.75 (73.00) 
2 52.30 (21.00) 52.50 (55.00) 114.10 (39.00) 60.75 (56.00) 
3 47.00 (10.00) 52.65 (41.00) 104.00 (152.00) 49.00 (55.00) 
4 37.00 (44.00) 48.00 (12.00) 102.70 (155.00) 44.60 (52.00) 
5 0 43.70 (68.00) 101.80 (156.00) 33.62 (68.00) 
6 0 45.50 (65.00) 89.03 (148.00) 32.77 (55.00) 
Total Energy 221.50 (124.40) 302.45 (236.90) 538.10 (733.80) 275.85 (254.60) 
 
 
4.3 Pain 
Pain scores (VAS) reduced for 27 of the 28 participants. The median pain score 
for the cohort reduced from 6 (IQR=3) at baseline to 2 (IQR=4) at 6 month follow 
up, a statistically significant reduction (p<0.001). 
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Analysis of median pain score between each clinical time point and for each wound 
healing outcome (table 11), shows a statistically significant reduction between 
measurements for those who healed their wound (p<0.001), for those achieving 
≥50% reduction of surface area (p<0.001) and for those achieving ≤50% area 
reduction (p=0.006). 
 
Table 9 - Median pain score 
Outcome 
Median pain score (VAS) (IQR)  at each clinical time point Friedman test 
p value Baseline 6 weeks 12 weeks 6 months 
Healed 4 (3) 2 (3) 0 0 <0.001 
Reduced by ≥50% 5 (2) 3 (4) 2 (1) 2 (3) <0.001 
Reduced by ≤50% 8 (3) 5 (1) 5 (1) 5 (2) 0.006 
Total cohort 6 (3) 3 (3) 2 (4) 2 (4) <0.001 
Outcome 
Median pain score (VAS) (IQR)  at each clinical time point Wilcoxon test 
p value Baseline 6 months 
Total cohort 6 (3) 2 (4) <0.001 
 
 
4.4 Exudate 
At 6 month follow up the number of participants with an exudate level recorded 
as ‘high’ at baseline reduced from 9 to 1 and those recorded as ‘medium’ reduced 
from 18 to 5. Analysis of the equality of frequencies between baseline and 6 month 
follow up (table 12), shows the reduction of exudate levels to be statistically 
significant (p<0.001). First reduction of exudate occurred at median 6 weeks 
(IQR=4), after 3 ECSW treatments. 
Observation of exudate levels at each clinical time point (table 13) shows a 
tendency for poorer outcomes to be associated with higher baseline exudate levels 
(p>0.05). 
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Table 10 - Variance of exudate levels at baseline and 6 months 
Baseline 
exudate 
Exudate at 6 month follow up 
None Low Medium High Total 
None 0 0 0 0 0 
Low 1 0 0 0 1 
Medium 7 8 3 0 18 
High 0 6 2 1 9 
Total 8 14 5 1 28 
 
Table 11 - Exudate levels at each clinical time point 
Outcome 
Exudate levels at each clinical time point 
Baseline 6 weeks 12 weeks 6 months 
Low Med High Low Med High Low Med High Low Med High 
Healed 1 8 0 5 3 0 1 0 0 1 0 0 
Reduced by ≥50% 0 9 3 4 8 0 10 2 0 10 2 0 
Reduced by ≤50% 0 1 6 1 3 3 3 3 1 3 3 1 
Total cohort 1 18 9 10 14 3 14 5 1 14 5 1 
 
 
4.5 Quality of life 
4.5.1 SF-36 physical and mental component scores 
SF-36 physical component scores (table 14) improved for 22 of the 28 
participants. For the total cohort, improvement with statistical significance was 
shown from baseline to 6 month follow up (p<0.001) and between each clinical 
time point (p<0.001). 
There was a tendency for SF-36 physical component scores to be higher, indicating 
better QOL, at 12 weeks and 6 months in those participants who healed their 
ulcer. Scores improved with statistical significance between clinical time points for 
those who healed their wound (p=0.014) and for those achieving >50% area 
reduction (p=0.044). 
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SF-36 mental component scores (table 15) improved for 21 of the 28 participants. 
For the total cohort, improvement with statistical significance was shown from 
baseline to 6 month follow up (p=0.003) and between each clinical time point 
(p=0.004). However, when individual wound healing outcomes were analysed, no 
statistical significance was shown between clinical time points for those who 
healed their wound (p=0.127), those achieving >50% area reduction (p=0.069) 
or for those achieving ≤50% area reduction (p=0.232). 
Comparison of mean SF-36 physical and mental component scores at each clinical 
time point is illustrated in table 16. 
 
Table 12 - SF-36 physical component scores  
Outcome 
Clinical time point Repeat measures ANOVA 
p value Baseline (SD) 6 weeks (SD) 12 weeks (SD) 6 months (SD) 
Healed 36.19 (10.79) 39.48 (10.71) 45.68 (11.33) 46.22 (9.70) 0.014 
Reduced by ≥50% 35.40 (10.62) 35.33 (11.22) 39.00 (12.13) 39.51 (12.34) 0.044 
Reduced by ≤50% 30.02 (10.27) 30.85 (9.21) 35.46 (6.09) 37.60 (4.06) 0.077 
Total cohort 34.31 (10.50) 35.55 (10.73) 40.26 (11.07) 41.19 (10.32) <0.001 
Outcome 
Clinical time point Paired t-test 
p value Baseline (SD) 6 months (SD) 
Total cohort 34.31 (10.50) 41.19 (10.32) <0.001 
 
Table 13 - SF-36 mental component scores  
Outcome 
Clinical time point Repeat measures ANOVA 
p value Baseline (SD) 6 weeks (SD) 12 weeks (SD) 6 months (SD) 
Healed 51.11 (6.91) 51.09 (5.69) 53.53 (4.43) 54.44 (4.50) 0.127 
Reduced by ≥50% 44.51 (6.62) 47.82 (8.59) 48.06 (7.32) 48.42 (7.64) 0.069 
Reduced by ≤50% 46.03 (6.36) 45.77 (7.60) 46.86 (6.22) 49.03 (5.23) 0.232 
Total cohort 47.01 (7.04) 48.36 (7.54) 49.52 (6.66) 50.51 (6.59) 0.004 
Outcome 
Clinical time point Paired t-test 
p value Baseline (SD) 6 months (SD) 
Total cohort 47.01 (7.04) 50.51 (6.59) 0.003 
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Figure 8 – Comparison of mean SF-36 component scores 
  
 
 
 
4.5.2 EQ-5D index scores 
EQ-5D index scores (table 17) improved for 27 out of 28 participants. For the total 
cohort, improvement with statistical significance was shown from baseline to 6 
month follow up (p<0.001) and between each clinical time point (p<0.001). 
The EQ-5D score was higher, indicating greater QOL, at 12 weeks and 6 months 
in participants who healed their wound. EQ-5D scores improved with statistical 
significance between clinical time points for those who healed their wound 
(p=0.002) and for those achieving >50% area reduction (p=0.025). 
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Table 14 - EQ-5D index scores  
Outcome 
Clinical time point Repeat measures ANOVA 
p value Baseline (SD) 6 weeks (SD) 12 weeks (SD) 6 months (SD) 
Healed 0.77 (0.10) 0.78 (0.98) 0.91 (0.11) 0.91 (0.11) 0.002 
Reduced by ≥50% 0.70 (0.56) 0.70 (0.56) 0.77 (0.10) 0.77 (0.12) 0.025 
Reduced by ≤50% 0.68 (0.62) 0.68 (0.77) 0.72 (0.65) 0.76 (0.79) 0.058 
Total cohort 0.71 (0.81) 0.72 (0.86) 0.80 (0.12) 0.81 (0.12) <0.001 
Outcome 
Clinical time point Paired t-test 
p value Baseline (SD) 6 months (SD) 
Total cohort 0.71 (0.81) 0.81 (0.12) <0.001 
 
 
 
4.5.3 CXVUQ scores 
Disease specific, CXVUQ scores (table 18) improved for 21 of the 28 participants. 
For the total cohort, improvement with statistical significance was shown from 
baseline to 6 month follow up (p<0.001) and between each clinical time point 
(p<0.001). 
The greatest improvement at 12 weeks and 6 months is seen in participants who 
healed their wound. CXVUQ scores improved with statistical significance between 
clinical time points for those who healed their wound (p<0.001), those achieving 
≥50% area reduction (p=0.035) and for those achieving ≤50% area reduction 
(p=0.024). 
Table 15 - CXVUQ scores  
Outcome 
Clinical time point Repeat measures ANOVA 
p value Baseline (SD) 6 weeks (SD) 12 weeks (SD) 6 months (SD) 
Healed 62.67 (12.13) 58.33 (14.53) 29.56 (17.26) 29.00 (15.10) <0.001 
Reduced by ≥50% 65.42 (6.86) 67.67 (7.56) 61.93 (8.25) 62.08 (10.44) 0.035 
Reduced by ≤50% 76.71 (13.72) 76.57 (12.20) 69.56 (6.87) 59.68 (6.03) 0.024 
Total cohort 67.36 (11.67) 66.89 (12.96) 53.43 (10.39) 50.85 (18.85) <0.001 
Outcome 
Clinical time point Paired t-test 
p value Baseline (SD) 6 months (SD) 
Total cohort 67.36 (11.67) 50.85 (18.85) <0.001 
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4.6 Summary of key results 
At 6 months: 9 wounds had healed, 12 had a ≥50% reduction in surface area and 
7 had a less than <50% reduction. For the cohort, the rate of healing = 1.91cm2 
(IQR=2.77) per week. Median time to complete wound healing outcome was 8 
weeks. Median time to ≥50% reduction outcome was 10 weeks. 
Baseline ulcer area tended to be smaller and the ulcers were of shorter duration 
in the healed group compared to those achieving ≤50% area reduction. Higher 
baseline BMI appears to be associated with poorer outcomes. Higher levels of 
exudate at baseline also appears to correlate with poorer outcomes. 
Pain scores significantly reduced for 27 participants (96%); significant reduction 
was apparent at a median 4 weeks. Exudate levels also significantly reduced for 
27 participants; significant reduction was apparent at median 6 weeks. 
SF-36 physical and mental component scores as well as EQ-5D index scores 
showed significantly improved QOL for total cohort. Greatest improvement 
occurred in those that healed. Disease specific CXVUQ scores showed significantly 
improved QOL for the total cohort and between clinical time points regardless of 
clinical outcome. 
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CHAPTER 5 - DISCUSSION 
5.1 Introduction 
The primary aim of this study was to assess the clinical effectiveness of ECSW in 
terms of ulcer healing when used in combination with multilayer compression 
therapy. The secondary aim was to determine the effect of ECSW on participant 
reported ulcer pain, exudate levels and QOL. 
In the following chapter the various outcomes of this study will be discussed in 
the context of the existing knowledge base. As a pilot study, consideration will 
also be given to the limitations of the study, its design and its implications for 
future research and practice. 
 
5.2 Interpretation of results 
5.2.1 Wound healing 
In terms of the primary outcome measure, 9 participants (32%) achieved 
complete wound closure and remained healed at 6 months. The median time to 
complete wound closure for the group of 9 participants achieving this outcome 
was 8 weeks. 
The secondary outcome measure of a ≥50% wound area reduction, occurred in a 
further 12 participants (43%); for these 12 participants the median time to 
achieve this outcome was 10 weeks. 
5 participants (18%) achieved a ≤50% wound area reduction; 2 (7%) participant’s 
wounds remained unchanged. No wounds deteriorated. 
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The rate of complete wound healing obtained in this study is considerably less 
than the 70% achieved utilising multilayer compression bandaging alone in a 
number of RCTs where ulcer duration average was 7.5 months and baseline wound 
area 9cm2. (Kikta, Schuler et al. 1988, Charles 1991, Colgan, Teevan et al. 1996, 
Cordts, Hanrahan et al. 1992). There are a number of potential reasons why 
similar healing rates were not achieved in this study. 
Firstly, this study’s sample was mainly composed of patients who had failed to 
heal their ulcers with multilayer compression therapy in primary care and had 
therefore been referred to a specialist clinic in a secondary care environment. This 
is reflected in the long median duration of ulcers in this study (13.5 months, 
IQR=14). 
The participants in this study all had large ulcers (median area 22.89cm2, 
IQR=36.49). Studies have repeatedly suggested that venous ulcers ≥5cm2 in area 
and of duration ≥6months are least likely to heal utilising multilayer compression 
therapy alone (Nelson 2001b, Phillips, Machado et al. 2000, Parker, Finlayson et 
al. 2015). It is known that patients age is a key prognostic factor in the healing of 
venous ulcers, with many studies suggesting delayed wound healing associated 
with the over 65 age group (Thomas 2001, Labropoulos, Wang et al. 2012). Within 
this study the median age was 69 years; 17 participants (61%) were over the age 
of 65 years. It can therefore be surmised that the sample consisted of chronic, 
hard to heal wounds which had not responded to multilayer compression therapy 
alone and were unlikely to. 
Previous case series have shown wound healing rates of around 30% with ECSW 
therapy in the treatment of a diverse range of wound types. Thus the 32% wound 
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healing rate in this study is comparable (Schaden, Thiele et al. 2007, Saggini, 
Figus et al. 2008). 
The study contains insufficient numbers of participants with multiple ulcers to 
make significant comparisons. However, of the three participants with multiple 
ulcers, the primary wound treated with ECSW reduced in size at a faster average 
rate (0.43cm2 per week) when compared to the secondary wound which did not 
receive ECSW (0.09cm2 per week). In all three cases neither primary nor 
secondary wound achieved complete wound closure. 
The secondary wound healing outcome of a ≥50% reduction in wound area 
occurred in a larger proportion of the cohort. It is of interest that this group had 
ulcers which tended to be of a smaller ulcer area and of shorter duration than 
those who healed. It is noted that pre-treatment levels of exudate were higher in 
those wounds which did not heal but achieved a ≥50% wound area reduction and 
are yet higher still in the group achieving ≤50% wound area reduction. This 
suggests that higher baseline exudate levels may reduce the ability of ECSW to 
achieve healing. Studies have suggested that in some cases venous ulcer exudate 
may inhibit the process of angiogenesis, the very process that ECSW may seek to 
encourage (Drinkwater, Smith et al. 2002, Ulrich, Lichtenegger et al. 2005, Wang, 
Yang et al. 2011). 
Body habitus may also have influenced wound healing outcome. There was a trend 
for participants who healed their wound to be around healthy BMI compared to 
those who achieved ≥50% and ≤50% wound area reduction who were mainly 
overweight or obese. Several studies have suggested that being overweight may 
contribute to the mechanism of venous insufficiency development (Van Rij, De 
Alwis et al. 2008, Willenberg, Schumacher et al. 2010). In addition, studies 
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examining wound healing in general have proposed that being overweight or 
clinically obese, may be an intrinsic factor affecting healing, not least attributable 
to impaired tissue perfusion (Guo, Dipietro 2010, Pierpont, Dinh et al. 2014). 
Obesity and poor nutrition are unarguably linked; the implication of poor nutrition 
in wound healing being that the body does not receive enough of the proteins and 
vitamins essential for wound healing (Collins 2003, Wilson, Clark 2003). 
The relationship between amount of shock wave energy administered and wound 
healing outcome remains unclear. Though the same amount of energy per cm2 
was delivered to all wounds, there was a trend for larger amounts of energy to be 
delivered to those achieving ≤50% wound area reduction. This is simply 
attributable to larger baseline ulcer areas for this group equating to the calculation 
of larger shock wave energy doses for application, perhaps reinforcing the 
relevance of baseline ulcer size as prognostic factor for healing. 
 
5.2.2 Pain and exudate   
It has been established through review of studies which include QOL data and 
patient experience that pain is the foremost concern and complaint of those who 
suffer with chronic venous ulceration (Cooper, Hofman et al. 2003, González‐
Consuegra, Verdú 2011). There are several key points to note when considering 
the effect that ECSW had upon patient reported pain scores within this study. 
From baseline to 6 month follow up pain scores reduced for 27 of the 28 
participants, 96% of the cohort. Statistical significance was shown for the 
improvement regardless of wound healing outcome, suggesting that the treatment 
had an effect upon pain independent of wound healing itself. Pain scores began to 
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reduce on average after 2 ECSW treatments. Furthermore, the reduction of 
median pain score for the cohort from 6 at baseline to 2 at 6 month follow up 
equates to a 36% shift on an 11 point VAS, constituting a clinically significant 
reduction. 
Multilayer compression therapy alone has not been shown to impact upon patient 
reported pain levels, indeed it is known that a leading reason for noncompliance 
with compression bandaging is often cited as high levels of ongoing pain and 
discomfort (Edwards 2003, Briggs, Closs 2006). The findings in this study are 
supported by the widely reported analgesic effect of low energy ECSW particularly 
in the treatment of orthopaedic conditions (Rompe, Hopf et al. 1996, Han, Lee et 
al. 2015). Two analgesic mechanisms are suggested; the first postulates that the 
application of shock waves initiates degeneration of epidermal nerve fibres leading 
to pain relief (Ohtori, Inoue et al. 2001). The second mechanism focuses upon the 
ability of shock waves to alter the tissue concentration of substance P, an 
important element involved in pain perception (Maier, Averbeck et al. 2003). 
Within this study it appears that ECSW had a statistically significant impact upon 
exudate levels over the course of the study with the number of participants whose 
exudate level was recorded as ‘high’ at baseline reducing from 9 to 1 and those 
recorded as ‘medium’ reducing from 18 to 5 at 6 month follow up. 
 
5.2.3 Quality of life 
Studies have repeatedly shown that the greatest impact chronic venous ulceration 
has upon people’s lives is through physical pain, impaired mobility and a reduced 
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ability to carry out the daily activities of living (Hopman, VanDenKerkhof et al. 
2014, Faria, Blanes et al. 2011). 
This is demonstrated in the direct comparison of baseline SF-36 physical and 
mental component scores in this study. At baseline, participants mean physical 
component score (34.31, SD=10.50) began at a much lower point than their 
mental component score (47.01, SD=7.04); similarly, SF-36 data reported in 
previous studies showed a tendency for physical component scores to be lower at 
baseline than mental component scores (Charles 2004, Clarke-Moloney, O’Brien 
et al. 2005). 
QOL improved for the cohort throughout treatment with ECSW, regardless of 
wound healing outcome. For SF-36 questionnaires, the physical component score 
showed the most improvement with mental component scores also improving, 
albeit less dramatically. Physical and mental component scores improved with 
statistical significance for the whole cohort, with greatest improvement noted in 
those who healed their wound. Clinical significance was shown for change in mean 
physical component score which improved by 6.88 points, within the Minimally 
Important Difference (MID) range of a 5 to 10 point shift. Improvement in mean 
mental component score was not shown to be clinically significant, represented by 
a 3.5 point shift in score. 
Similarly, previous studies of multilayer compression therapy have shown physical 
component scores tend to show greater improvement than mental component 
scores, particularly amongst those whose wound healed. (Charles 2004, Clarke-
Moloney, O’Brien et al. 2005). 
In the context of a cohort which had not responded to multilayer compression 
therapy, this would suggest the addition of ECSW produced QOL improvements 
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comparable to studies reporting the benefits of multilayer compression therapy, 
current best practice. Furthermore, EQ-5D questionnaire scores in this study 
followed the trend of SF-36 physical component scores with an improvement in 
QOL for the cohort as a whole and greatest improvement shown in those who 
healed their wound. Clinical significance was also established with mean EQ-5D 
index score improving by 0.1 points on the index scale; MID range of score shift 
required for EQ-5D having been established as 0.08 to 0.1. 
Perhaps the most unexpected result comes by way of disease specific CXVUQ 
scores. Disease specific QOL questionnaires are an important measurement tool; 
they focus upon specific clinical changes in unique conditions and are considered 
more sensitive than their generic counterparts (Morgan, Crayford et al. 2001, de 
Vries, Ouwendijk et al. 2005, Engelhardt, Spech et al. 2014). 
CXVUQ scores showed statistically significant QOL improvements for the cohort as 
a whole, for those who healed their wound, those who achieved ≥50% wound area 
reduction, but most impressively for those who achieved ≤50% wound area 
reduction. This indicates that QOL improved without the occurrence of significant 
wound healing. Pain and high levels of wound exudate dramatically impact upon 
the QOL of those who suffer chronic venous ulceration; our results indicate that 
the addition of ECSW reduces these factors, contributing to improved QOL.  
Many of the studies investigating compression therapy predate the inception of 
the CXVUQ, making direct comparisons difficult. One recent RCT reporting 
compression therapy outcomes showed improvement of CXVUQ score from mean 
baseline (28.6, SD=17.9) to 6 month follow up (22.4, SD=16.5), a 6.2 point 
reduction (Wong, Andriessen et al. 2012).  
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In this study, mean CXVUQ score improved from baseline (67.36, SD=11.67) to 
6 month follow up (50.85, SD=18.85), a 16.51 point reduction. Mean baseline 
ulcer area varies greatly: 7.8cm2 in the compression study versus 22.89cm2 in 
this study. Despite a greater reduction between scores, QOL at 6 months appears 
poorer in this study than for the compression study. However, baseline CXVUQ 
score in this study was far higher and ulcer sizes far greater. It is difficult to discuss 
clinical significance in the absence of reported and validated Minimally Important 
Differences (MID) for CXVUQ scores. 
 
5.2.4 Safety 
No unexpected adverse events or serious adverse events were recorded 
throughout the duration of this study. Of the expected non-serious adverse events 
only very minor wound bleeding was encountered. None of the studied ulcers 
required treatment for wound infection and there were no reports of discomfort 
derived directly from the study treatment. 
 
5.3 Limitations of the study 
As a pilot, reporting of the limitations of this study, its design and components is 
of great import. The elements which worked well led to the successful reporting 
of results and prompted discussion of findings. What follows should not only help 
critique this study but help to improve and inform future studies. 
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5.3.1 Sample size and population 
The number of participants in this study is small when compared to many of the 
prior RCTs investigating multilayer compression bandaging. The limitation of a 
small sample size occurs primarily in the use of statistical analysis and the 
generalisability of results (Campbell, Machin 1990, Button, Ioannidis et al. 2013). 
Several trends emerged in analysis of study results without statistical significance 
being shown, potentially due to the small number of participants being studied. 
This identifies the risk of potential type II statistical errors, the failure within 
statistical analysis to detect an effect that is present (Anthony 1999). Yet this was 
a pilot study, examining a specific and new hypothesis; there is merit in utilising 
a smaller sample size in this type of study where the new hypothesis can be tested 
or research question answered without the resources of a larger study (Parahoo 
2006). 
The population from which the sample was chosen may also be viewed as a 
limitation of the study. Analysis of participant demographics established that the 
sample represents a group who fall into the category of ‘hard to heal wounds’, 
mainly elderly patients referred to a specialist clinic in the secondary care 
environment. The wounds themselves were large and of long duration thus truly 
chronic in nature. The sample recruited met the requirement of those suffering 
chronic venous ulceration, what was perhaps undervalued was the severity of the 
particular cases included. 
A different recruitment strategy could have been considered in order to capture a 
more representative sample. This would consist of less chronic presentations of 
the condition, personifying a wider range of ages, wound sizes and ulcer durations, 
most likely found in the primary care setting. Alternatively, the potential role of 
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ECWS could be regarded as an adjuvant to multilayer compression therapy in the 
hard to heal wound group. 
 
5.3.2 Study design 
The study is of a simple, quasi-experimental, time series design without a separate 
control group. The lack of control group may limit the potential of this study, some 
would even class this as a critical limitation (Ho, Peterson et al. 2008). Without a 
control group it can be difficult to eliminate alternate explanations for study results 
(Burns, Grove et al. 2011). Within this study there is an element of historic control 
whereby specific but historic criteria, some of which matches the type of data 
collected within the study, is known about each participant. Of this historic control 
data, perhaps most importantly, the duration for which the wound has remained 
unhealed and the duration of compliance with multilayer compression therapy 
alone prior to entry into the study is known. Although this does not replace the 
benefit of a separate control group, in this exploratory study it allows us to begin 
to see the relationship between study treatment and improved outcomes for 
individual participants and for the cohort as a whole. Historic controls are however 
susceptible to confounding factors and for the purposes of comparison, are not as 
reliable as randomising participants to a treatment or control group (Parahoo 
2006, Burns, Grove et al. 2011). Therefore in this pilot study data from historic 
controls has not been employed in statistical analysis, it is instead utilised as a 
context against which to consider results. 
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Undoubtedly herein lies the potential for further research and the progression to 
an RCT, the primary benefit of which would be increased internal validity of the 
study through the addition of randomly designated treatment and control groups. 
 
5.3.3 Risk of bias 
Selection bias is often cited as the greatest threat to the internal validity of a 
study; it occurs when participants are selected on the basis of a variable that is 
associated with the outcome and is often affiliated with non-randomised studies 
(Parahoo 2006, Boswell, Cannon 2014). An appropriate example would be the 
selection of participants with small wounds of short duration as they are most 
likely to heal during the course of the study. Randomisation helps to remove 
selection bias (Newell, Burnard 2011); however it has shown that the sample in 
this study consists mainly of participants least likely to respond to treatment. 
There remains a risk of this being perceived as selection bias in the opposite 
direction; the likelihood however is that risk of selection bias is low. 
Within the study there does exist a risk of performance bias, whereby the cohort 
may have been exposed to influencing factors other than the treatment being 
studied (Parahoo 2006, Boswell, Cannon 2014). By attending study appointments 
participants received the time, care and attention of specialist nursing staff in an 
environment which differs from their usual, routine care. The argument could be 
made that outcomes were potentially influenced by the addition of specialist care 
and attention. This could have been avoided through the use of blinding 
methodology to reduce performance bias, masking personnel and participants to 
differences in treatment (Polit, Beck 2013). 
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5.3.4 Economic analysis 
This study focused upon clinical outcomes and did not consider the financial 
implication of the treatment or its delivery. Factors considered in other studies 
analysing the cost of compression therapy have included the value of dressings 
and bandaging systems, nurse’s time, administration, travel and overhead costs 
for the facility delivering care (Olin, Beusterien et al. 1999, O'Brien, Grace et al. 
2003). The use of ECSW as an adjuvant to compression therapy clearly adds 
financial cost in the purchase or hire and maintenance of a shock wave lithotripter. 
However, when utilised in a group unresponsive to compression therapy there 
may be an offset between increased treatment cost and reduced time to healing. 
 
5.4 Implications for practice 
ECSW appears to show potential as an adjuvant treatment in the healing and 
management of chronic venous ulceration alongside multilayer compression 
bandaging. It represents a treatment modality which led to improved wound 
healing outcomes in 75% of the ulcers studied (32% complete wound closure), all 
of which had remained static and unhealed for 13.5 months on average. Though 
further research is required, ECSW should be regarded as a safe treatment worthy 
of consideration in the treatment and management of this chronic condition. 
Primary and secondary wound healing outcomes, along with pain and exudate 
reductions were achieved within a time frame of 12 weeks. Similarly, the greatest 
improvements in QOL were observed within the same time frame. 
There are many variables in the delivery of this treatment which may affect its 
effectiveness and the time period in which outcomes may be achieved. Exploration 
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of contrasting treatment durations and frequency intervals, as well as variations 
of delivered energy levels and pulse frequencies should be considered in future 
studies. 
The results of this study have direct implications for nursing practice and the 
delivery of patient centred care. Outcomes indicate that ECSW potentially offers a 
beneficial, therapeutic option in the care of patients not responding to multilayer 
compression therapy. The benefit to patients QOL alone justifies consideration of 
this treatment and certainly merits the attention of future nurse led study. 
 
5.5 Future research needs 
The results of this pilot study have shown that there is a clear requirement for 
further research into the use of ECSW to treat chronic venous ulceration. An RCT 
of greater sample size based upon a power calculation, potentially recruiting from 
primary care, is justified and would provide the methodology required to better 
define and demonstrate treatment effect. There is potential for the application of 
this treatment beyond the group of patients who fail to respond to compression 
therapy alone; the selection of any future sample should attempt to address this 
in its recruitment strategy improving the generalisability of results. 
The relationship between amount of shock wave energy delivered and outcome 
requires further exploration, as does the role of baseline wound exudate as an 
influence upon treatment efficacy. 
Unusually, no wound infections were encountered throughout the study; a further 
research pathway would be to investigate any potential antimicrobial effect that 
ECSW may impart. 
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CHAPTER 6 - CONCLUSION 
In this study, ECSW achieved wound closure in 32% of participants with a further 
43% achieving a ≥50% wound area reduction. Participant reported pain scores 
and exudate levels reduced for 96% of participants treated with ECSW. 
QOL, measured with generic and disease specific tools, improved for the whole 
cohort over the studied six month period regardless of wound healing outcome. 
ECSW should be regarded as a safe therapy worthy of consideration in the 
treatment and management of this chronic condition. Its role in the treatment of 
small ulcers of short duration is unclear; however for large ulcers, of long duration, 
not responding to multilayer compression therapy, there appears to be substantial 
benefit. 
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Summary of studies included in literature review 
 
Reference Study design Population and 
characteristics 
Intervention 
and control 
Outcome 
category 
Results 
primary outcome and 
statistics 
Level of 
evidence 
SIGN 
Weakness/limitations 
Mittermayer 2012 Literature 
review 
Wounds of varying 
aetiology. 7 studies 
included of which 2 
include venous 
stasis ulcers. 
  
Focused and 
unfocused 
electrohydraulic 
shockwave. 0.037 
to 0.15mJ/mm2 
energy. Pulses per 
cm2 vary from 
100 to 500. 
Complete wound 
healing. Time to 
complete healing 
(rate).  
One study shows poorest 
shockwave response in 
venous stasis ulcer group. 
No statistical analysis. 
1++ No meta-analysis of 
data. 
Qureshi 2011 Literature 
review 
Preclinical studies in 
animals, in vitro 
studies, prospective 
and retrospective. 8 
studies included, 
only 2 included 
venous stasis ulcers. 
Focused and 
unfocused 
shockwave. 0.037 
to 0.1mJ/cm2. 
Reduction of 
wound size. 
Complete wound 
healing. 50% 
wound healing. 
Pain reduction.  
36% of venous ulcers 
complete healing and 
significant pain reduction 
in one study. 
Venous stasis ulcers worst 
responders in study 
comparing various wound 
aetiologies. 
1++ No QOL measure. 
No exudate measure 
Saggini 2008 Clinical trial Intervention group 
30, control group 
10. Chronic lower 
limb ulceration. 
Posttraumatic, 
venous stasis and 
diabetic ulcers. 
Focused 
shockwave. 0.037 
mJ/mm2 energy 
at 4Hz. Treatment 
repeated every 
two weeks – 
minimum 4, 
maximum 10 
sessions. Two 
groups, standard 
treatment and 
standard plus 
shockwave. 
Wound row 
surface area. NBS 
self-assessment. 
Pain scale. 
Exudate amount. 
Intervention group 
16 ulcers healed (4 
venous). Significant 
difference row surface 
area and exudate 
(p<0.01). Analysis of NBS 
scores showed significant 
decrease of pain 
(p<0.001). 
 
2+ 
No randomisation. 
No QOL measure. 
No follow up period. 
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Stieger 2013 Case study Single patient case 
study. Chronic 
venous leg ulcer. 
2000 pulses per 
session – 0.25 
mJ/mm2 energy 
at 4Hz. Weekly 
treatments – 30 
sessions. 
Complete wound 
healing. Time to 
complete wound 
healing. 
Complete re-
epithelialisation achieved 
at 30 weeks/sessions. 
Recurrence of ulcer at 
two weeks post healing.  
3/4 Single case study. 
Short follow up 
period. 
No QOL measure. 
No pain or exudate 
measure. 
Focused or 
unfocused? 
Fioramonti 2012 Case study Single patient case 
study. Chronic, 
bilateral venous leg 
ulcer. 
100 pulses per 
cm2 at 
0.037mJ/mm2 
energy – 4Hz. 
Weekly 
treatment, 6 
sessions. Right leg 
treated 
shockwave – left 
leg conventional 
dressings only. 
Complete healing. 
 
Right leg ulcers 
(shockwave) healed at 6 
weeks. Left leg (dressings 
only) unhealed at 6 
weeks. 
3/4 Single case study. 
No follow up period. 
No QOL measure. 
No pain measure. 
No exudate measure. 
Schaden 2006 Feasibility 
study 
208 patients – 
nonhealing acute 
and chronic soft-
tissue wounds. 
25 (12%) wounds 
venous stasis ulcer. 
Follow up at 44 
days 
100 to 1000 
pulses per cm2 at 
0.1mJ/mm2. 1 – 2 
weekly, 3 
treatment 
maximum. 
Complete healing. 15.4% drop out. 
156 (75%) complete 
wound healing. 
16 venous stasis ulcers 
reduced in size but did 
not heal, 9 achieved 
complete wound healing. 
Overall, venous stasis 
ulcers achieved worst 
healing rates (36%) 
2+ No QOL measure. 
No pain measure. 
No exudate measure. 
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Wolff 2011 Observational 
study 
282 patients – 
chronic soft tissue 
wounds of which 38 
were venous ulcers. 
Single group 
assignment (one 
armed, open, 
prospective.). 
Median follow up 
38 months. 
Unfocussed 
shockwave - 
0.1mJ/mm2 
energy – median 
pulses 167 per 
cm2. 
Weekly then two 
weekly treatment 
– 10 weeks. 
Successful wound 
closure. 
 
The influence of 
comorbidities failed to 
meet significance level (p 
< 0.01). 
Logistic regression 
analysis - wound 
duration, initial surface 
area and initial wound 
bed score shown to 
influence shockwave 
success. 
2+ Non-randomised. 
Undefined follow up 
period. 
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Background 
Description of the condition 
Leg ulcers are chronic wounds most commonly described as open lesions of the skin occurring below the knee on 
the leg or foot, further characterised by healing times of greater than six weeks (SIGN 2010; Van Gent 2010). The 
causes of leg ulceration are varied and often multifactorial; primary aetiological factors include venous 
insufficiency, arterial insufficiency and diabetes (Mekkes 2003). 
Venous ulceration is the most common type of leg ulceration seen in the community. Studies have shown that for 
people with chronic leg ulcers, 70% to 80% of those ulcers have a venous component (Valencia 2001; Crane 2008). 
Chronic venous leg ulceration has an estimated prevalence of 1% to 2% of the population in developed countries. 
Point prevalence for the United Kingdom (UK) is estimated to be between 0.3% and 0.5% (per 1000 population), 
which increases with age (Reichenberg 2005; Vowden 2009; González Consuegra 2011). The natural history of the 
disease is one of a continuous cycle of healing and breakdown over decades (Smith 2006; Raju 2010). 
Venous ulceration is associated with impaired quality of life, reduced mobility, pain, stress and loss of dignity 
(Persoon 2004; Wilson 2004). Social isolation can be commonplace and is frequently associated with malodorous 
wounds, swelling and anxiety around exudate levels (Walters 1999; Herber 2007). 
Venous ulcers arise as a result of venous valve incompetence and calf muscle pump insufficiency (Palfreyman 
1998; Mekkes 2003), which leads to retrograde venous flow, venous hypertension, microcirculatory skin changes 
and localised tissue damage. Two main mechanisms have been proposed to account for the tissue damage and 
subsequent ulceration that occurs. The fibrin cuff hypothesis postulates that venous hypertension leads to 
exudation of fibrin, a protein involved in the clotting of blood, into the surrounding tissues, and leads to the 
formation of fibrin cuffs around capillaries which impairs gas exchange, leading to tissue damage (Smith 2006). The 
leucocyte- (white blood cell) trapping hypothesis postulates that leucocytes which have become trapped in the 
microcirculation migrate into surrounding tissues and lead to an inflammatory response with impairment of 
normal proliferation and skin healing (Saharay 1998; Hahn 1999). 
The current gold standard in the management of chronic venous leg ulcers revolves around high compression 
multilayer bandaging (SIGN 2010). Multilayer compression bandaging aims to improve venous return and reduce 
venous hypertension (Valencia 2001; Etufugh 2007). Elastic multi-component bandages such as four layer 
bandaging and comparative two layer systems are used; these consist of an initial layer of orthopaedic wool, a 
crepe bandage, an elastic bandage and an elastic cohesive bandage as the outer layer (Marston 1999). The high 
pressure is sustained for a considerable time allowing for a weekly change of dressings. With multilayer 
compression therapy, healing rates of around 70% at six months have been achieved in specialist clinics. Simple, 
nonadherent primary wound dressings are currently recommended in conjunction with compression bandaging 
(SIGN 2010). Other known treatments for this condition include the use of various impregnated primary dressings, 
hyperbaric oxygen therapy and treatment of underlying venous insufficiency via surgery, endovenous laser (EVLT), 
radiofrequency (RFA) and sclerotherapy treatments. 
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Description of the intervention 
Extracorporeal shock waves (ECSWs) are low energy pulse waves that were first put to clinical use in the treatment 
of urolithiasis, whereby kidney stones (urinary calcinosis) are broken up by the shock wave energy (Shrivistava 
2005). Since then their application has been extended to the treatment of fractured bones with an interrupted 
healing process (non-union fractures), tendon injury and osteonecrosis, a condition whereby bone breaks down 
faster than it can be replenished (Schaden 2007). More recently, the ability of ECSWs to improve the healing of 
wounds, ulcers and burns has been assessed. The incidental discovery that shock waves may have an effect upon 
wound healing was made in 2006 (Schaden 2007; Arno 2010; Mittermayr 2011); the treatment in this context has 
remained novel. 
Shock waves carry energy, have a short life cycle and are able to travel through a physical medium such as liquid or 
gas. Shock waves are generated through the transformation of electric energy into mechanical energy. This 
transformation can occur in one of three ways: electromagnetic generation utilises a strong magnetic field to 
create a slow, low pressure acoustical pulse; piezoelectric generation relies upon the rapid contraction and 
expansion of piezoelectric crystals, achieved through the application of a high voltage pulse; and electrohydraulic 
generation utilises a shock wave pulse released by high voltage electrode water vaporisation (Ogden 2001; 
Mouzopoulos 2007). 
Shock waves are defined by their waveform, number and frequency of impulses, and energy flux density (the rate 
at which energy is transferred through the physical medium). Standardised, disease-specific protocols pertaining 
to the use of shock wave therapy in wound care are lacking (Schaden 2007). In the treatment of wounds, lower 
flux densities are typically used, providing lower energy levels. Regardless of their characteristics or mode of 
generation, shock waves can be delivered to a target area either in a focused or dispersed manner through the use 
of specific applicator units (Mittermayr 2011). 
All three modes of shock wave generation, electromagnetic, piezoelectric and electrohydraulic, are found in 
current clinical practice. Both focused and un-focused (dispersed) applicator units have been utilised in the 
delivery of treatment for soft tissue wounds, with typical energy levels of 0.037mJ/mm to 0.1mJ/mm (Schaden 
2007; Saggini 2008). 
 
How the intervention might work 
In humans, ECSWs have been shown to promote the formation and development of blood vessels (angiogenesis) 
and to reduce inflammation (Wang 2011).The mechanism of how ECSW therapy may aid wound healing is poorly 
understood at present, however several animal model studies have shown increased levels of signal proteins 
(vascular endothelial growth factor (VEGF) and factor HIF-1alpha) following treatment. These proteins are in part 
responsible for the restoration of tissue oxygen supply when blood circulation is inadequate (Chen 2004; Nishida 
2004; Wang 2004; Ma 2007). This angiogenic process is stimulated by the application of ESCWs and plays an 
important role in wound healing (Stojadinovic 2008; Mittermayr 2011). In addition ECSW application may, through 
the application of shear stress forces, alter the physical properties of endothelial cells. 
 
Why it is important to do this review 
Venous ulceration is a common, chronic condition resulting in significantly impaired quality of life and substantial 
burden to all healthcare systems. The use of shock waves in the treatment of venous leg ulcers is an as yet novel 
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therapy; a comprehensive review of all relevant and available randomised controlled trials is required to inform 
practice. 
 
Objectives 
To assess the effects of extracorporeal shock wave therapy in the healing and management of venous leg 
ulceration.  
Methods 
Criteria for considering studies for this review 
Types of studies 
We will include randomised controlled trials (RCTs) reporting an objective measure of wound healing (see 'Types 
of outcome measures'). There will be no restriction on the basis of language, publication status or age of study. 
 
Types of participants 
People over the age of 18 years, from any care setting and socio-economic background, with active lower limb 
ulceration of venous aetiology. Guidelines in the UK indicate assessment of ankle brachial indices should be 
performed to rule out arterial disease, and many diagnostic assessments will also include duplex ultrasound 
imaging to identify venous reflux (SIGN 2010); we will accept studies in which a diagnosis of venous ulceration has 
been made irrespective of whether the ankle brachial indices were reported. 
Studies will be included where lower limb venous ulceration is either the focus of the study or is included within a 
study evaluating a broader range of soft tissue wounds. In the case of the latter, results will be stratified according 
to wound aetiology. 
 
Types of interventions 
Studies evaluating the use of low energy, focused or non-focused extracorporeal shock waves (ECSWs) in the 
context of soft tissue wound treatment. 
Eligible comparators will include: 
ECSW compared with no treatment or sham treatment 
ECSW compared with dressings (with or without compression treatment) 
ECSW compared with alternative treatment - for example truncal venous surgery (including endovenous 
laser treatment, radiofrequency and sclerotherapy), hyperbaric oxygen therapy Head to head comparisons 
of varying types, modes and strengths of ECSW treatment. 
Shock waves produced by any of the three accepted methods will be included; these comprise electrohydraulic, 
electromagnetic and piezoelectric principles of shock wave generation. We will exclude studies examining ECSW 
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use for the treatment of chronic tendinopathies, impaired bone healing function, urinary and biliary calcinosis and 
myocardial ischaemia. 
 
Types of outcome measures 
Primary outcomes 
Complete wound healing measured by: 
• Time to complete wound healing 
• Proportion of index ulcers completely healed over a six month period 
• Adverse effects, including participant-reported pain from intervention (measured using a visual 
analogue scale, such as a numeric box scale. (NBS) 
Secondary outcomes 
• Change in ulcer size (percentage change from baseline) 
• Quality of life (measured using a standardised generic questionnaire such as: 
EQ-5D, SF-36, SF-12 or SF-6) 
• Effect upon volume of exudates (utilising subjective measurement, such as low, medium, high) 
• Effect upon daily ulcer pain (measured using a visual analogue scale, such as an NBS 
Ulcer recurrence (defined as a new lesion in the skin where complete healing had 
occurred) Treatment cost. 
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Search methods for identification of studies 
Electronic searches 
We will search the following electronic databases: 
• The Cochrane Wounds Group Specialised Register 
• The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, 
latest issue) 
• Ovid MEDLINE (1946 to present) 
• Ovid MEDLINE (In-Process & Other Non-Indexed Citations) 
• Ovid EMBASE (1974 to present) 
• EBSCO CINAHL (1982 to present). 
We will use the following provisional search strategy in CENTRAL and will adapt it as appropriate for 
the other databases: 
#1 MeSH descriptor: [Ultrasonic Surgical Procedures] explode all trees  
#2 MeSH descriptor: [Ultrasonic Therapy] explode all trees  
#3 MeSH descriptor: [Sound] this term only  
#4 MeSH descriptor: [High-Energy Shock Waves] explode all trees  
#5 (Shockwave* or (shock* near wave*)) (Word variations have been searched)  
#6 Ultraso*:ti,ab,kw  
#7 Lithotrip*:ti,ab,kw  
#8 ESWT:ti,ab,kw  
#9 ECSW:ti,ab,kw  
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9  
#11 MeSH descriptor: [Leg Ulcer] explode all trees  
#12 ((varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or (stasis next ulcer*) or 
(crural next ulcer*) or "ulcus cruris" or "ulcer* cruris"):ti,ab,kw  
#13 #11 or #12  
#14 #10 and #13 
We will combine the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for 
identifying randomised trials in MEDLINE: sensitivity and precision maximising version (2008 
revision) (Lefebvre 2011). We will combine the EMBASE search with the Ovid EMBASE filter 
developed by the UK Cochrane Centre (Lefebvre 2011). We will combine the CINAHL searches with 
the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN 2014). There will 
be no restrictions with respect to language, date of publication or study setting. We will also search 
the following clinical trials registries: 
• ClinicalTrials, gov (http://www.clinicaltrials.gov/) 
 112 
 
• WHO International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/Default.aspx) EU Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/). 
Searching other resources 
We will examine the reference lists of all identified, relevant studies in order to locate further 
studies not highlighted by the electronic search. We will identify and contact experts and industry 
representatives to enquire about unpublished or ongoing studies. 
 
Data collection and analysis 
Selection of studies 
The assessment of studies for potential inclusion will be undertaken by two independent review 
authors (PB, BC). References drawn from initial searches will be examined for relevance; studies 
considered for inclusion will be retrieved in full and selected according to the criteria for considering 
studies for this review described above. Any disagreement regarding the selection of studies for 
inclusion will be resolved by discussion with a third review author (JB). 
We will include a study flow diagram as recommended by the PRISMA statement (Liberati 2009) to 
illustrate the results of all searching activity and the process of screening and selecting studies for 
inclusion in the review. 
 
Data extraction and management 
A data extraction sheet will be utilised by two review authors (PB, BC) to summarise eligible studies. 
In cases where multiple publications have arisen from a study, one publication will be identified as 
the primary reference but all studies will be maximally data extracted. 
We will extract the following data: 
• Trial authors. 
• Year of publication. 
• Country where RCT performed. 
• Care setting. 
• Unit of investigation (participant, leg or ulcer). 
• Overall sample size and methods used to estimate statistical power. 
• Participant selection criteria. 
• Number of participants randomised to each treatment arm. 
• Baseline characteristics of participants per treatment arm (gender, age, baseline ulcer 
area and volume, ulcer duration, prevalence of co-morbidities such as diabetes, 
prevalence of clinically infected wounds or colonised wounds, previous history of 
ulceration, baseline levels of wound exudate, and participant mobility). 
• Details of the dressing/treatment regimen prescribed for each treatment arm including 
details of concomitant therapy (for example: compression). 
• Duration of treatment. 
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• Duration of follow-up. 
• Statistical methods utilised in data analysis. 
• Primary and secondary outcomes measured. 
• Primary and secondary outcome data by treatment arm. 
• Adverse effects of treatment (per arm with quantity and type). 
• Withdrawals (per treatment arm with quantity 
and reason). Source of trial funding. 
 
Assessment of risk of bias in included studies 
Two review authors (PB, BC) will independently assess each included study using the Cochrane tool 
for assessing risk of bias (Higgins 2011).This tool addresses six specific domains: sequence 
generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting 
and other potential sources of bias (for this review, baseline comparability of groups for factors such 
as surface area and duration of ulcer). RCTs will be classified as being at an overall high risk of bias if 
they are rated as 'high risk' for any one of three key domains: allocation concealment, blinded 
outcome assessment of healing, and completeness of outcome data. RCTs will be classified as being 
at an overall low risk of bias if rated as 'low risk' in the three key domains of allocation concealment, 
blinded outcome assessment of healing, and completeness of outcome data. 
Individual assessments will be made of participant blinding and blinding of outcome assessors. We 
will present our assessment of risk of bias using two 'Risk of bias' summary figures; one which is a 
summary of bias for each item across all studies, and a second which shows a cross-tabulation of 
each trial by all of the 'Risk of bias' items. Disagreements between review authors will be resolved 
through discussion with a third review author (JB). 
 
Measures of treatment effect 
Data analysis will be performed according to the guidelines of the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins 2011). One review author will enter quantitative data 
into Review Manager 5.3, another will check it, and the data will be analysed using RevMan 5.3. We 
will present the outcome results for each trial with 95% confidence intervals (CI). 
We will report estimates for dichotomous outcomes (e.g. ulcers healed during time period, number 
of infected ulcers) as risk ratios (RR). 
Continuous outcomes (such as changes in ulcer area) will be expressed as mean differences (MD) 
and overall effect size (with 95% CI calculated) or as standardised mean differences (SMDs) if 
different methods of measurement are used in the studies. 
Time-to-event data will be analysed utilising survival, time-to-event approaches, with adjustment for 
baseline size if data are available. We plan to plot, and, if feasible, pool, estimates of hazard ratio 
and 95% CI as presented in the trial reports using the generic inverse variance method in RevMan 
5.3. 
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Unit of analysis issues 
We will record whether included studies present outcomes in relation to a wound, a participant or as 
multiple wounds on the same participant. We will analyse the level at which study randomisation 
has occurred. 
Dealing with missing data 
Review authors will attempt to contact the trial investigators in cases of missing data. Where trials 
report complete healing outcomes for only those participants who complete the trial (i.e. 
participants withdrawing and lost to follow-up were excluded from the analysis), we will treat the 
participants who were not included in the analysis as if their wound did not heal. Where trials report 
results for participants who complete the trial without specifying the numbers initially randomised 
per group, we will present only complete case data. For other outcomes the same analysis will be 
applied. 
Assessment of heterogeneity 
We will consider clinical heterogeneity (where trials appear different in terms of participant 
characteristics, intervention type and duration and outcome type) and statistical heterogeneity. We 
will assess statistical heterogeneity using the Chi test (P values less than 0.10 will be considered to 
indicate significant heterogeneity) in conjunction with the I statistic (Higgins 2003). The I statistic 
estimates the percentage of total variation across trials due to heterogeneity rather than variation 
due to chance. Heterogeneity will be categorised as follows: I values of 40% or less will indicate a low 
level of heterogeneity, and values of 75% or above will represent very high heterogeneity. 
 
Assessment of reporting biases 
If possible, funnel plots will be used to assess reporting bias if a minimum of 10 studies are available 
for the meta-analysis of a primary outcome (Sterne 2011). 
 
Data synthesis 
We will present a narrative overview of the studies reviewed, and will utilise RevMan 5.3 to combine 
outcomes where possible. Included trials will be grouped according to the comparator intervention, 
which may include no treatment, standard dressings, biological dressings, compression, venous 
surgery, other novel therapy, varying types, modes and strengths of shock wave therapy and sham 
treatment. The decision to include studies in a meta-analysis will depend on the availability of 
treatment effect data and assessment of heterogeneity. 
For comparisons for which there is no apparent clinical heterogeneity and the I value is 40% or less, 
we will apply a fixed-effect model. Where there is no apparent clinical heterogeneity and the I value 
is greater than 40%, we will apply a random-effects model. However, we will not pool data where 
heterogeneity is very high (I values of 75% and above). We will grade the quality of the evidence for 
each primary outcome (complete wound healing measured by the number of ulcers completely 
healed within the duration of the trial and adverse events) using four levels of quality: high, 
moderate, low and very low (Schunemann 2011a). 
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The following factors will be graded: 
• Limitations in the design and implementation of available studies, suggesting high 
likelihood of bias 
• Indirectness of evidence (indirect population, intervention, control, outcomes) 
• Unexplained heterogeneity or inconsistency of results (including issues with 
subgroup analyses) Imprecision of results (wide confidence intervals) High 
probability of publication bias. 
 
 
'Summary of findings tables' 
We will present the main results of the review in 'Summary of findings' tables. These tables present 
key information concerning the quality of the evidence, the magnitude of the effects of the 
interventions examined, and the sum of the available data for the main outcomes (Schunemann 
2011a). The 'Summary of findings' tables also include an overall grading of the evidence related to 
each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, 
Development and Evaluation) approach. The GRADE approach defines the quality of a body of 
evidence as the extent to which one can be confident that an estimate of effect or association is 
close to the true quantity of specific interest. The quality of a body of evidence involves 
consideration of within-trial risk of bias (methodological quality), directness of evidence, 
heterogeneity, precision of effect estimates and risk of publication bias (Schunemann 2011b). We 
plan to present the following outcomes in the 'Summary of findings' tables: 
• Time to complete wound healing 
• Proportion of index ulcers completely healed over a six month period 
• Adverse effects, including participant-reported pain from intervention (measured using a 
visual analogue scale, such as a numeric box scale. (NBS). 
Subgroup analysis and investigation of heterogeneity 
Potential sources of heterogeneity will be considered and every effort will be made to extract 
sufficient, compatible data to undertake subgroup analysis of individuals. Subgroups will include 
demographic divisions, variations in type of shock wave treatment and differing durations of follow-
up. 
 
Sensitivity analysis 
We plan to undertake sensitivity analyses to explore the influence of risk of bias on effect size. We 
will also assess the influence of removing from meta-analyses, studies classed as having an overall 
high risk of bias. These analyses will include only studies that are assessed as having a low risk of bias 
in all key domains, namely allocation concealment, blinded outcome assessment of healing, and 
completeness of outcome data for the estimates of treatment effect. 
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PARTICIPANT INFORMATION SHEET 
Extracorporeal shockwave for the treatment of chronic venous ulcers: 
A Pilot study 
 
Introduction 
You are being invited to take part in a local study. Before you decide, it is important for you 
to understand why the research is being done and what it will involve. Please take time to 
read the following information and feel free to ask any questions if you would like more 
information. Take time to decide whether or not you wish to take part. Thank you for taking 
the time to read this information sheet. 
 
Venous ulcers are breaks in the skin of the legs which occur in people who have increased 
pressure in their leg veins (venous disease). The ulcers are treated with dressings and 
compression bandages which are applied by a specialist nurse. The success of this treatment 
varies and it may take up to 6 months or longer for the ulcer to heal.  
 
This study aims to see if an additional treatment known as extracorporeal shock wave therapy 
can improve the healing rates of patients with venous ulcers. Extracorporeal shockwave are 
low energy shock waves which have been shown in studies involving patients to improve the 
healing of some wounds. They may act by helping tiny new blood vessels to grow and reducing 
the number of cells which cause inflammation. Shock waves may also improve the healing of 
venous ulcers but further studies are required to determine if this is the case. 
 
We have used shock wave therapy in our ward for the past year. Further information is 
required to help us determine if shock wave therapy when used with routine care can improve 
healing rates and hence the need for this study.  
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What is the purpose of the study? 
We wish to find out if shockwave therapy can improve the healing of venous leg ulcers when 
used alongside routine care (dressings and bandages).   
Why I have been chosen? 
You have been invited because you have been diagnosed as having a leg ulcer (break in your 
skin) which has occurred due venous disease.    
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form (you will be given a copy). If you 
decide to take part you are still free to withdraw at any time and without giving a reason. This will not 
affect the standard of care you receive. Even if you decide not to take part, your future treatment will 
not be affected. 
   What will happen to me if take part? 
If you do decide to take part we will contact you and then arrange a convenient time for you 
to come up to ward 36 at Aberdeen Royal Infirmary to answer any further questions you might 
have. If you are still happy to proceed we will ask you to sign a consent form. You will then 
undergo shock wave therapy in addition to the standard routine care of your leg ulcer(s). If 
you have more than 1 leg ulcer then only one, which will usually be the worst one in terms of 
appearance and size will be treated with the shock waves. 
You will receive shock wave therapy every two weeks in the outpatient clinic setting. This 
involves putting some cling film over the ulcer and then applying some gel to aide conduction 
of shock wave pulses. These will be applied in short bursts for approximately 10 - 15 minutes.  
Number of shock wave treatments: Initially you will receive 3 shock wave treatments. If there 
is found to be an improvement in the ulcer the treatments will be continued at 2 weekly 
intervals to a maximum of 6 treatment sessions in total. You will then continue the standard 
routine care (dressings and bandages) in the community until the ulcer is healed. You will be 
asked to attend for review back at the clinic at 6 months from entering the study.   
If after 3 treatments there is no improvement in your ulcer, we will discontinue the shock 
wave therapy but will continue with the normal standard ulcer care (dressings and bandages) 
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in the community. We would still wish to follow you up in the study and see you back at the 
ward at 2 further visits at 3 and 6 months.  
If your ulcer is not healed by 6 months you will continue to be treated and followed in the 
NHS. 
What else will I be asked to do as part of the study? 
When you attend you will be asked some questions about how painful your ulcers are and if 
you have experienced any symptoms during the study. You will also be asked to complete a 
short questionnaire at every clinic visit, including follow up visits at 6 weeks, 3 months and 6 
months. 
What are the possible disadvantages of taking part? 
You may experience some mild discomfort and minor bleeding of your ulcer during the shock 
wave treatment. Rarely patients may experience a reaction to the shock wave leading to 
redness of the ulcer. 
Will my taking part in this study be kept confidential? 
The information obtained from your medical records and records created, as a part of the 
study will be checked to make sure the information is accurate. It will then be transferred to 
a database and processed to analyse the results of the study. The final results may be 
published for scientific purposes. All information collected about you during the course of 
study will be kept strictly confidential. Any information which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. If you are 
agreeable we would wish to let your General Practitioner know you are taking part in this 
study. 
What will happen to the results of the research study? 
The results of the study may be used in presentations at scientific meetings and/or published 
in scientific journals but no one will be able identify you. We will let you know the results of 
the study when it finishes. 
Who is organising and funding the research? 
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The study group is headed by Professor Julie Brittenden and is organised by the Division of 
Applied Medicine at the University of Aberdeen and the Department of Vascular Surgery at 
Aberdeen Royal Infirmary. The funding for this study is from a local endowment grant. 
Has this study been approved? 
The study has been reviewed and approved by the North of Scotland Research Ethics 
Committee. 
Contact for further information 
If you have any questions about participation please feel free to ask Professor Julie Brittenden 
or Mr Paul Bachoo who can provide further information. 
Dr Brittenden can be contacted on 01224 559446, or 0845456 6000, bleep 3363 
If you would like independent advice or have any questions about the research, you can 
contact: Mr Euan Munro, Consultant Vascular Surgeon, Aberdeen Royal Infirmary - or - NHS 
Grampian Research and Development Office, Foresterhill House Annexe, Foresterhill, 
Telephone 01224 551121.   
If you take part in this study you will be given a copy of the information sheet and a signed 
consent form to keep. 
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Consent Form 
Extracorporeal shockwave for the treatment of chronic 
venous ulcers - Pilot Study  
Please initial box 
 
1 I confirm that I have read and understand the information sheet 
dated 22/06/13 (version 2) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
2 I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
 
3 I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from the University of 
Aberdeen, from regulatory authorities or from the NHS Trust/Health Board, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
 
4 I give permission for photographs to be taken during treatment for assessment. 
    
 
 
5 I agree to my GP being informed of my participation in the study. 
    
 
 
6 I agree to take part in the above study.    
  
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
_________________________ ________________ ____________________ 
Researcher Date Signature 
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Letter to GP 
 
Dear Doctor,  
  
Extracorporeal shockwave for the treatment of chronic venous ulcers: 
A pilot  study 
 
Your patient has agreed to take part in the above study and has given us permission to 
inform you. This study aims to see if extracorporeal shock wave therapy in addition to 
standard dressings and multilayer compression therapy can improve the healing rates of 
patients with venous ulcers. 
 
Extracorporeal shockwave are low energy shock waves which have been shown in studies 
involving patients to improve the healing of some wounds. They may act by promoting 
angiogenesis and reducing local inflammation, Shock waves may also improve the healing 
of venous ulcers but further studies are required to determine if this is the case. We have 
used shock wave therapy in our ward for the past year. This observational study is required 
to help us determine if shock wave therapy when used with routine care can improve healing 
rates of venous ulcers.  
 
Your patient will receive shock wave therapy every two weeks in the outpatient clinic setting. 
If after 3 treatment sessions there is found to be an improvement in the ulcer the treatments 
will be continued at 2 weekly intervals to a maximum of 6 treatment sessions in total. Your 
patient will then continue the standard routine care (dressings and bandages) in the 
community until the ulcer is healed. If there has been no improvement after 3 sessions they 
will continue with standard care. Patients will be followed up for 6 months in the study. 
Please feel free to contact me if you wish any further information of have any queries or 
concerns. 
 
Yours sincerely 
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Appendix E 
 
Baseline data collection form 
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Baseline/Demographic Data collection 
 
Participant name  
NHS CHI  
Body Mass Index  
Age  
Employment status and type  
Socioeconomic status  
Residence  
Level of mobility  
Comorbidities  
Current medications  
Allergies  
Duration of current episode of ulceration  
Number of previous episodes of ulceration  
Length of time since first venous ulcer  
Previous intervention for venous insufficiency  
Varicose vein assessment - CEAP  
ABI – Left leg  
ABI – Right leg  
Duration of current compression therapy  
  
Ultrasound assessment – venous anatomy  
SFJ  
CFV  
SPJ  
POP  
GSV  
SSV  
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Baseline Ulcer assessment 
 
Number of active ulcers  
Reference ulcer number  
Ulcer appearance  
Edge  
Base  
Area ulcer 1  
Area ulcer 2  
Area ulcer 3  
Area ulcer 4  
Volume ulcer 1  
Volume ulcer 2  
Volume ulcer 3  
Volume ulcer 4  
Venous skin changes  
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Documentation pertaining to ethical approval 
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NHS Grampian  Prof Julie Brittenden  
  Consultant Vascular Surgeon &  
  Chair in Surgery, Aberdeen University  
    
  j.brittenden@abdn.ac.uk  
    
    Ben Cooper   
Vascular Specialist Nurse  
  
bencooper@nhs.net  
  
      
    
JB/BC  
Date 21/06/2013  
  
Dear Dr Johnstone,  
Reference: 13/NS/0053  
Thank you for your letter regarding the above study. We are most disappointed with the opinion of 
the committee and feel that many of the issues raised can easily be addressed. In response to the 
points raised by the committee we have revised the ethical form, protocol and patient information 
leaflet.   
We would be most grateful if the committee would consider this revised application in light of our 
responses. We believe that we have addressed all the issues raised.  The principal investigator, Julie 
Brittenden apologises that she was unable to attend in person to the meeting on the 13th June will 
endeavour to attend in person for the next meeting.  
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Design of proposed study:   
Response: This is an observational study. This is clearly stated in the protocol (protocol, 
section 6) and the ethical application (IRAS, A1, A7, A13).  
Previous study:  
Response: This was a retrospective safety/feasibility study only (protocol, section 5). We 
have no information regarding efficacy – we are unclear what effect if any,  ECSW will have 
on healing rates of patients with venous ulcers who are undergoing standard compression 
therapy.   
We apologise if it was not clear to the committee that this study is not repetitive. There is 
no available literature to inform us on the efficacy of ECSW therapy in patients with venous 
ulcers undergoing standard recommended compression therapy. We would like to reassure 
the committee that we are not repeating the same study.  
The table below clearly summarises the differences. These differences have now been 
highlighted in the revised protocol.  
  
  Previous study  Current study  
Inclusion criteria    
Non-compliant to conventional treatment  Included  Excluded  
Design  Retrospective  
Feasibility study  
Prospective  
Observational study  
Follow-up period  None  6 months  
Number of treatment sessions  Not defined  
(mean 6 sessions)  
3 initial sessions  
3 further if responding  
Primary End-points    
Ulcer healing rates at 6 months  Not assessed  To be assessed  
Quality of life at six months  Not assessed  To be assessed  
Secondary End-points    
Ulcer pain  Assessed  To be assessed  
Exudate levels  Assessed  To be assessed  
Ulcer recurrence  Not assessed  To be assessed  
50% reduction in ulcer area  Assessed at 8 weeks only  To assess at 6 months  
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What is the Comparator?  
Response:  The SIGN guidelines on the management of venous ulcers and the Cochrane 
review clearly state expected healing rates of venous ulcers with standard compression 
therapy. These are specified at 12 and 24 weeks. We will assess the “gold-standard” 
outcome of complete ulcer healing at these time points. We have clarified this in the 
protocol (protocol, section 10).  
Intervention period:   
Response: We agree that this a chronic condition, but the reason for the intervention and 
follow-up period is addressed in point 3 above. Six months is the standard assessment 
period for studies in this area.   
5) Comparison of venous ulcer with contralateral ulcer if present  
Response: we have clearly stated in the protocol that “The patient may have more than 
one ulcer, situated on one or both legs. A single, reference ulcer will be selected for 
treatment; this will be the ulcer thought most likely to be the slowest healing in the 
view of the clinical team. This judgement may be based upon its size, duration or 
appearance (slough, exudate, presence of infection etc.)  
In patients with multiple ulcers, where the reference ulcer only will be treated with 
ECWS, the secondary ulcers will also be measured and rate of healing determined 
for comparison. In cases where a single ulcer is studied, rate of healing will be 
compared to rates reported in literature”.  
6)  Time for patient to consider taking part  
Response: We have already stated in the protocol and ethical application that potential 
participants will have a minimum of 24 hours to consider whether they wish to take part in 
this study (protocol, section 7) (IRAS, A6-2, A27-1, A30-1, A31).   
7) Recruitment  
Response: We apologise for any confusion here. We will only recruit patients at clinics and 
patients will not be a sent a letter. They will be informed of the trial and potentially 
interested patients will be given a copy of the patient information leaflet. A clinic log will be 
taken and potentially interested patients will be contacted by phone after the clinic. This 
has been corrected on the IRAS form (IRAS, A27-1).  
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8) Peer review  
This was done through the standard format as specified by the joint NHS 
Grampian/University of Aberdeen Sponsor. The educational supervisor has been heavily 
involved in the project and was a co-signature on the IRAS.  
9) University Logo  
Response: We apologise for this error. This has now been corrected.  
(See revised patient information sheet).  
10)  Best contact  
Response: We would be happy to exclude the best contact.  
(See revised protocol, section 15) (IRAS A37, A38).  
11)  Archiving  
Response:  Thank you for clarification. We will amend this to 10 years.  
(See revised protocol, section 15) (IRAS A43, A44).  
12)  Payment listed as benefit & potential benefits on patient information leaflet  
Response: We stated that there is no payment for participation but have now 
removed this following the committee’s comments. (See revised patient 
information sheet).  
Potential benefits - we do not know if this treatment will improve quality of life or 
healing rates and therefore cannot mention it as a potential benefit. (See revised 
patient information sheet) (IRAS A24).  
13)  3 copies of participant consent  
Response: We will photocopy the one signed consent form and file one copy in the medical 
notes, one copy in our study master file and one copy will be given to the patient as per 
good clinical practice.  
14)  Completion of Questionnaire at 6 weeks  
Response: Apologies, we have now included the 6 week time point in the patient 
information leaflet and revised protocol.  
(Please see revised patient information sheet) (protocol, section 6).  
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15)  Committee noted that this was the nurse specialist’s first project  
Response: This project is being done as part of an Msc. The nurse specialist will be 
supervised by both an experienced PI and educational supervisor. The PI and educational 
supervisor were unable to attend the meeting due to clinical/educational commitments and 
are of the opinion that many of the issues raised could have been addressed if they had the 
opportunity to attend.   
16)  Conflict of interest regarding treating and collecting the data  
Response: Thank you for raising this issue. We would like to reassure the committee that 
this is not an issue for the primary outcome measures.   
The primary outcome measures are: 1) Time to complete healing - we have stated in the 
protocol that if the ulcer heals, a digital photograph will be taken and analysed by 2 
independent assessors. 2) QOL- which is patient reported. The patients will either complete 
this form before they see the research nurse or return it by post.  
17)  Reasons for only treating one leg in bilateral cases  
Response: We have no evidence that this treatment will improve ulcer healing rates.  
18)  Pain induced by treatment  
Response: We have stated that patients may experience some minor discomfort and 
bleeding (protocol, section 11) (IRAS A18).  
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Research and Development  
Mr Ben Cooper NHS Grampian  
Ward 36 - Aberdeen Royal Infirmary  
Department Of Vascular Surgery  
Foresterhill Road  
Aberdeen  
AB25 2ZN  
          
  
Dear Mr  Cooper  
  
Foresterhill House Annexe  
Foresterhill  
ABERDEEN  
AB25 2ZB  
  
  
Date    08/10/2013  
Management Permission for Non-Commercial Research  
  
STUDY TITLE:  Extracorporeal shockwave for the treatment of chronic venous ulcers: An 
observational study      
PROTOCOL NO:  v2.0; 22 June 2013  
REC REF:  13/NS/0084    
  
Thank you very much for sending all relevant documentation.  I am pleased to confirm that the project is now 
registered with the NHS Grampian Research & Development Office.  The project now has R & D Management 
Permission to proceed locally.  This is based on the documents received from yourself and the relevant 
Approvals being in place.  
  
All research with an NHS element is subject to the Research Governance Framework for Health and 
Community Care (2006, 2nd edition), and as Chief or Principal Investigator you should be fully committed to 
your responsibilities associated with this.  
  
It is particularly important that you inform us when the study terminates.  
  
The R&D Office must be notified immediately and any relevant documents forwarded to us if any of the 
following occur:  
  
 A change of Principal Investigator, Chief Investigator or any additional research personnel  
 Premature project termination  
 Any amendments – substantial or non-substantial (particularly a study extension)   Any 
change to funding or any additional funding   
  
We hope the project goes well, and if you need any help or advice relating to your R&D Management 
Permission, please do not hesitate to contact the office.  
  
Yours sincerely  
Project No  
  
2013VA002  
Enquiries to  Lynn Massie   
Extension  53846  
Direct Line  01224 553846  
Email  grampian.randdpermissions@nhs.net 
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Susan Ridge  
Non-Commercial Manager  
  
c.c. Professor Julie Brittenden  
c.c. Dr Gail Holland NHSG-RD-DOC-019 – V3.1 – R&D Management Permission Letter 
(Non CTIMP)  
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Ben Cooper 
Ward 36 
Aberdeen Royal Infirmary 
 
Date: 10th September 2013 
Research proposal number:   13-20 
Research proposal title:  Extracorporeal shockwave for the treatment of chronic venous ulcers: an 
observational study 
 
Dear Ben 
The School of Nursing and Midwifery Ethics Review Panel has now reviewed the above research 
proposal.  Please find details of the outcome and recommended actions below. 
 
 
 
 
 
* Where research involves NHS staff or patients, approval through the NRES system must be obtained. 
Members of the School Panel can advise on this process if necessary. 
Comments 
 
Proposal approved 
√ 
You may go ahead with your research, providing 
approval from any relevant external committee/s has 
been obtained.* 
 
Proposal approved subject to 
amendments.  
 
Please review and amend all relevant documents in 
the light of the comments given, then forward them 
to the Convenor who will give final approval. 
Proposal not approved: 
significant ethical issues as yet 
inadequately addressed. 
Please review your proposal in light of the issues 
identified. If you require further clarification or 
discussion please contact the Convenor. You are 
welcome to re-submit your proposal when the issues of 
     
 
 
 
 
Some proposals require consideration and input from 
colleagues outwith the School of Nursing and 
Midwifery. We will keep you informed of progress in 
this regard, and involved in the process as appropriate. 
Proposal referred to RES 
and/or the University Ethics 
sub committee. 
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Dear Ben 
 
Thank you for your clarification and minor amendments in response to the points raised in review. 
These are satisfactory and this letter confirms approval from the School’s Ethics Review Panel. 
 
Kind regards 
 
Dr Colin Macduff 
Acting Convenor 
School of Nursing and Midwifery Ethics Review Panel 
 
 
 
If you require further information please contact the Acting Panel Convenor, Colin Macduff on 01224 
262935 
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Appendix G 
 
Documentation pertaining to NHSG R&D monitoring 
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NHS Grampian  Ben Cooper  
Vascular Specialist Nurse Vascular Unit - Ward 507  
Aberdeen Royal Infirmary  
Foresterhill  
Aberdeen AB25 2ZN  
  
  Direct Line  (01224) 552571  
 Fax  (01224) 552553  
 Email to  bencooper@nhs.net  
  
Dear Diane,  
Thank you for the feedback following your recent study monitoring visit. Please see below list of 
action points highlighted and the actions now taken in response. Should any further information be 
required please do not hesitate to get back in touch. Many thanks  
 Ben Cooper  
  
Action points to be addressed  Action taken  
Signature missing on delegate log for Paul 
Bachoo  
Now completed by Paul Bachoo  
CV missing for Paul Bachoo  Now filed in TMF  
Ethics submission, response and approval 
missing from TMF  
Files located and now stored within TMF  
Signed consent forms stored with participant 
source docs and not TMF  
Rectified – signed consent forms now stored 
within TMF  
2 missing consent docs  Medical notes ordered to locate missing files  
Some details on consent forms filled in by 
researcher (date, printed name) – provide note 
to file  
Note to file added to TMF to explain reason for 
assisting several participants. In future this will 
not occur and participants will entirely complete  
Error correction incorrectly documented  Correct method discussed during site 
vist/monitoring. This will be utilised in future  
V1.1 info sheet described in consent V2  Correction made to corresponding docs  
Some consent form boxes ticked not initialled  Discussed during site visit – all future consent 
forms to be completed with initials  
Study number to be documented within space 
provided on consent form  
Rectified – existing forms completed and 
counter signed. Future consent forms will be 
correctly completed  
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